Darell D. Bigner, M.D., Ph.D. - Publications

Affiliations: 
Pathology and Surgery Duke University, Durham, NC 
Area:
Neuro-Oncology
Website:
http://pathology.mc.duke.edu/neuropath/np_faculty_dbigner.htm

327 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Chandramohan V, Bao X, Yu X, Parker S, McDowall C, Yu YR, Healy P, Desjardins A, Gunn MD, Gromeier M, Nair SK, Pastan IH, Bigner DD. Improved efficacy against malignant brain tumors with EGFRwt/EGFRvIII targeting immunotoxin and checkpoint inhibitor combinations. Journal For Immunotherapy of Cancer. 7: 142. PMID 31142380 DOI: 10.1186/s40425-019-0614-0  0.36
2019 Hansen LJ, Sun R, Yang R, Singh SX, Chen LH, Pirozzi CJ, Moure CJ, Hemphill C, Carpenter AB, Healy P, Ruger RC, Chen CJ, Greer PK, Zhao F, Spasojevic I, ... ... Bigner DD, et al. MTAP loss promotes stemness in glioblastoma and confers unique susceptibility to purine starvation. Cancer Research. PMID 31040154 DOI: 10.1158/0008-5472.CAN-18-1010  0.56
2019 Yu X, Dobrikov M, Keir ST, Gromeier M, Pastan IH, Reisfeld R, Bigner DD, Chandramohan V. Synergistic antitumor effects of 9.2.27-PE38KDEL and ABT-737 in primary and metastatic brain tumors. Plos One. 14: e0210608. PMID 30625226 DOI: 10.1371/journal.pone.0210608  0.36
2019 Lipp ES, Healy P, Austin A, Clark A, Dalton T, Perkinson K, Herndon JE, Friedman HS, Friedman AH, Bigner DD, McLendon RE. MGMT: Immunohistochemical Detection in High-Grade Astrocytomas. Journal of Neuropathology and Experimental Neurology. 78: 57-64. PMID 30500933 DOI: 10.1093/jnen/nly110  0.56
2018 Diplas BH, Liu H, Yang R, Hansen LJ, Zachem AL, Zhao F, Bigner DD, McLendon RE, Jiao Y, He Y, Waitkus MS, Yan H. Sensitive and rapid detection of TERT promoter and IDH mutations in diffuse gliomas. Neuro-Oncology. PMID 30346624 DOI: 10.1093/neuonc/noy167  0.56
2018 Lei K, Sun R, Chen LH, Diplas BH, Moure CJ, Wang W, Hansen LJ, Tao Y, Chen X, Chen CJ, Greer PK, Zhao F, Yan H, Bigner DD, Huang J, et al. Mutant allele quantification reveals a genetic basis for TP53 mutation-driven castration resistance in prostate cancer cells. Scientific Reports. 8: 12507. PMID 30131529 DOI: 10.1038/s41598-018-30062-z  0.52
2018 Desjardins A, Gromeier M, Herndon JE, Beaubier N, Bolognesi DP, Friedman AH, Friedman HS, McSherry F, Muscat AM, Nair S, Peters KB, Randazzo D, Sampson JH, Vlahovic G, Harrison WT, ... ... Bigner DD, et al. Recurrent Glioblastoma Treated with Recombinant Poliovirus. The New England Journal of Medicine. PMID 29943666 DOI: 10.1056/NEJMoa1716435  0.56
2018 Xie L, Lin C, Zhang Q, Piao H, Bigner DD, Zhang Z, Bao X. Elevated expression of podoplanin and its clinicopathological, prognostic, and therapeutic values in squamous non-small cell lung cancer. Cancer Management and Research. 10: 1329-1340. PMID 29872344 DOI: 10.2147/CMAR.S163510  0.36
2018 Diplas BH, He X, Brosnan-Cashman JA, Liu H, Chen LH, Wang Z, Moure CJ, Killela PJ, Loriaux DB, Lipp ES, Greer PK, Yang R, Rizzo AJ, Rodriguez FJ, Friedman AH, ... ... Bigner DD, et al. The genomic landscape of TERT promoter wildtype-IDH wildtype glioblastoma. Nature Communications. 9: 2087. PMID 29802247 DOI: 10.1038/s41467-018-04448-6  0.56
2018 Gedeon PC, Schaller TH, Chitneni SK, Choi BD, Kuan CT, Suryadevara CM, Snyder DJ, Schmittling RJ, Szafranski SE, Cui X, Healy P, Herndon JE, McLendon RE, Keir ST, Archer GE, ... ... Bigner DD, et al. A rationally designed fully human EGFRvIII:CD3-targeted bispecific antibody redirects human T cells to treat patient-derived intracerebral malignant glioma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29703821 DOI: 10.1158/1078-0432.CCR-17-0126  0.56
2018 Keir ST, Chandramohan V, Hemphill CD, Grandal MM, Melander MC, Pedersen MW, Horak ID, Kragh M, Desjardins A, Friedman HS, Bigner DD. Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models. Journal of Neuro-Oncology. PMID 29564747 DOI: 10.1007/s11060-018-2832-6  0.56
2017 Waitkus MS, Pirozzi CJ, Moure CJ, Diplas BH, Hansen LJ, Carpenter AB, Yang R, Wang Z, Ingram BO, Karoly ED, Mohney RP, Spasojeic I, McLendon RE, Friedman HS, He Y, ... Bigner DD, et al. Adaptive evolution of the GDH2 allosteric domain promotes gliomagenesis by resolving IDH1(R132H) induced metabolic liabilities. Cancer Research. PMID 29097607 DOI: 10.1158/0008-5472.CAN-17-1352  0.56
2017 Reap E, Suryadevara CM, Batich KA, Sanchez-Perez L, Archer GE, Schmittling RJ, Norberg PK, Herndon JE, Healy P, Congdon KL, Gedeon PC, Campbell OC, Swartz AM, Riccione KA, Yi JS, ... ... Bigner DD, et al. Dendritic cells enhance polyfunctionality of adoptively transferred T cells which target cytomegalovirus in glioblastoma. Cancer Research. PMID 29093005 DOI: 10.1158/0008-5472.CAN-17-0469  0.56
2017 Yang R, Chen LH, Hansen LJ, Carpenter AB, Moure CJ, Liu H, Pirozzi CJ, Diplas BH, Waitkus MS, Greer PK, Zhu H, McLendon RE, Bigner DD, He Y, Yan H. Cic loss promotes gliomagenesis via aberrant neural stem cell proliferation and differentiation. Cancer Research. PMID 28939681 DOI: 10.1158/0008-5472.CAN-17-1018  0.56
2017 Brown MC, Holl EK, Boczkowski D, Dobrikova E, Mosaheb M, Chandramohan V, Bigner DD, Gromeier M, Nair SK. Cancer immunotherapy with recombinant poliovirus induces IFN-dominant activation of dendritic cells and tumor antigen-specific CTLs. Science Translational Medicine. 9. PMID 28931654 DOI: 10.1126/scitranslmed.aan4220  0.32
2017 Chandramohan V, Bryant JD, Piao H, Keir ST, Lipp ES, Lefaivre M, Perkinson K, Bigner DD, Gromeier M, McLendon RE. Validation of an Immunohistochemistry Assay for Detection of CD155, the Poliovirus Receptor, in Malignant Gliomas. Archives of Pathology & Laboratory Medicine. PMID 28829151 DOI: 10.5858/arpa.2016-0580-OA  0.56
2017 Pirozzi CJ, Carpenter AB, Waitkus MS, Wang CY, Zhu H, Hansen LJ, Chen LH, Greer PK, Feng J, Wang Y, Bock CB, Fan P, Spasojevic I, McLendon RE, Bigner DD, et al. Mutant IDH1 Disrupts the Mouse Subventricular Zone and Alters Brain Tumor Progression. Molecular Cancer Research : McR. PMID 28148827 DOI: 10.1158/1541-7786.MCR-16-0485  0.56
2016 Bao X, Pastan I, Bigner DD, Chandramohan V. EGFR/EGFRvIII-targeted immunotoxin therapy for the treatment of glioblastomas via convection-enhanced delivery. Receptors & Clinical Investigation. 3. PMID 28286803 DOI: 10.14800/rci.1430  0.48
2016 Yu X, Pegram CN, Bigner DD, Chandramohan V. Development and Validation of a Cell-Based Fluorescent Method for Measuring Antibody Affinity. Journal of Immunological Methods. PMID 28024998 DOI: 10.1016/j.jim.2016.12.004  0.36
2016 Chandramohan V, Pegram CN, Piao H, Szafranski SE, Kuan CT, Pastan IH, Bigner DD. Production and quality control assessment of a GLP-grade immunotoxin, D2C7-(scdsFv)-PE38KDEL, for a phase I/II clinical trial. Applied Microbiology and Biotechnology. PMID 28013405 DOI: 10.1007/s00253-016-8063-x  0.52
2016 Holl EK, Brown MC, Boczkowski D, McNamara MA, George DJ, Bigner DD, Gromeier M, Nair SK. Recombinant oncolytic poliovirus, PVSRIPO, has potent cytotoxic and innate inflammatory effects, mediating therapy in human breast and prostate cancer xenograft models. Oncotarget. PMID 27806313 DOI: 10.18632/oncotarget.12975  0.32
2016 Li F, Liu X, Sampson JH, Bigner DD, Li CY. Rapid reprogramming of primary human astrocytes into potent tumor initiating cells with defined genetic factors. Cancer Research. PMID 27364552 DOI: 10.1158/0008-5472.CAN-16-0171  0.56
2016 Svalina MN, Kikuchi K, Abraham J, Lal S, Davare MA, Settelmeyer TP, Young MC, Peckham JL, Cho YJ, Michalek JE, Hernandez BS, Berlow NE, Jackson M, Guillaume DJ, Selden NR, ... Bigner DD, et al. IGF1R as a Key Target in High Risk, Metastatic Medulloblastoma. Scientific Reports. 6: 27012. PMID 27255663 DOI: 10.1038/srep27012  0.56
2016 Thompson EM, Hielscher T, Bouffet E, Remke M, Luu B, Gururangan S, McLendon RE, Bigner DD, Lipp ES, Perreault S, Cho YJ, Grant G, Kim SK, Lee JY, Rao AA, et al. Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. The Lancet. Oncology. PMID 26976201 DOI: 10.1016/S1470-2045(15)00581-1  0.56
2016 Shiina S, Ohno M, Ohka F, Kuramitsu S, Yamamichi A, Kato A, Motomura K, Tanahashi K, Yamamoto T, Watanabe R, Ito I, Senga T, Hamaguchi M, Wakabayashi T, Kaneko MK, ... ... Bigner DD, et al. CAR T cells targeting podoplanin reduce orthotopic glioblastomas in mouse brains. Cancer Immunology Research. PMID 26822025 DOI: 10.1158/2326-6066.CIR-15-0060  0.56
2016 Hu J, Sun T, Wang H, Chen Z, Wang S, Yuan L, Liu T, Li HR, Wang P, Feng Y, Wang Q, McLendon RE, Friedman AH, Keir ST, Bigner DD, et al. MiR-215 Is Induced Post-transcriptionally via HIF-Drosha Complex and Mediates Glioma-Initiating Cell Adaptation to Hypoxia by Targeting KDM1B. Cancer Cell. 29: 49-60. PMID 26766590 DOI: 10.1016/j.ccell.2015.12.005  0.56
2016 Bao X, Chandramohan V, Reynolds RP, Norton JN, Wetsel WC, Rodriguiz RM, Aryal DK, McLendon RE, Levin ED, Petry NA, Zalutsky MR, Burnett BK, Kuan CT, Pastan IH, Bigner DD. Preclinical toxicity evaluation of a novel immunotoxin, D2C7-(scdsFv)-PE38KDEL, administered via intracerebral convection-enhanced delivery in rats. Investigational New Drugs. PMID 26728879 DOI: 10.1007/s10637-015-0318-3  0.56
2015 Okamura T, Antoun G, Keir ST, Friedman H, Bigner DD, Ali-Osman F. Phosphorylation of GSTP1 by EGFR Promotes Formation of the Inhibitory GSTP1-JNK Complex and Suppresses JNK Downstream Signaling and Apoptosis in Brain Tumor Cells. The Journal of Biological Chemistry. PMID 26429914 DOI: 10.1074/jbc.M115.656140  0.56
2015 Nair SK, Driscoll T, Boczkowski D, Schmittling R, Reynolds R, Johnson LA, Grant G, Fuchs H, Bigner DD, Sampson JH, Gururangan S, Mitchell DA. Ex vivo generation of dendritic cells from cryopreserved, post-induction chemotherapy, mobilized leukapheresis from pediatric patients with medulloblastoma. Journal of Neuro-Oncology. PMID 26311248 DOI: 10.1007/s11060-015-1890-2  0.56
2015 Flores C, Pham C, Snyder D, Yang S, Sanchez-Perez L, Sayour E, Cui X, Kemeny H, Friedman H, Bigner DD, Sampson J, Mitchell DA. Novel role of hematopoietic stem cells in immunologic rejection of malignant gliomas. Oncoimmunology. 4: e994374. PMID 25949916 DOI: 10.4161/2162402X.2014.994374  0.56
2015 Mitchell DA, Batich KA, Gunn MD, Huang MN, Sanchez-Perez L, Nair SK, Congdon KL, Reap EA, Archer GE, Desjardins A, Friedman AH, Friedman HS, Herndon JE, Coan A, McLendon RE, ... ... Bigner DD, et al. Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. Nature. 519: 366-9. PMID 25762141 DOI: 10.1038/nature14320  0.56
2015 Brown KE, Chagoya G, Kwatra SG, Yen T, Keir ST, Cooter M, Hoadley KA, Rasheed A, Lipp ES, Mclendon R, Ali-Osman F, Bigner DD, Sampson JH, Kwatra MM. Proteomic profiling of patient-derived glioblastoma xenografts identifies a subset with activated EGFR: implications for drug development. Journal of Neurochemistry. 133: 730-8. PMID 25598002 DOI: 10.1111/jnc.13032  0.56
2015 Schuster J, Lai RK, Recht LD, Reardon DA, Paleologos NA, Groves MD, Mrugala MM, Jensen R, Baehring JM, Sloan A, Archer GE, Bigner DD, Cruickshank S, Green JA, Keler T, et al. A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study. Neuro-Oncology. 17: 854-61. PMID 25586468 DOI: 10.1093/neuonc/nou348  0.56
2014 Wang H, Sun T, Hu J, Zhang R, Rao Y, Wang S, Chen R, McLendon RE, Friedman AH, Keir ST, Bigner DD, Li QJ, Wang H, Wang XF. miR-33a promotes glioma-initiating cell self-renewal via PKA and NOTCH pathways. The Journal of Clinical Investigation. 124: 4489-502. PMID 25202981 DOI: 10.1172/JCI75284  0.56
2014 Brown MC, Bryant JD, Dobrikova EY, Shveygert M, Bradrick SS, Chandramohan V, Bigner DD, Gromeier M. Induction of viral, 7-methyl-guanosine cap-independent translation and oncolysis by mitogen-activated protein kinase-interacting kinase-mediated effects on the serine/arginine-rich protein kinase. Journal of Virology. 88: 13135-48. PMID 25187541 DOI: 10.1128/JVI.01883-14  0.56
2014 Feng H, Lopez GY, Kim CK, Alvarez A, Duncan CG, Nishikawa R, Nagane M, Su AJ, Auron PE, Hedberg ML, Wang L, Raizer JJ, Kessler JA, Parsa AT, Gao WQ, ... ... Bigner DD, et al. EGFR phosphorylation of DCBLD2 recruits TRAF6 and stimulates AKT-promoted tumorigenesis. The Journal of Clinical Investigation. 124: 3741-56. PMID 25061874 DOI: 10.1172/JCI73093  0.56
2014 Brown MC, Dobrikova EY, Dobrikov MI, Walton RW, Gemberling SL, Nair SK, Desjardins A, Sampson JH, Friedman HS, Friedman AH, Tyler DS, Bigner DD, Gromeier M. Oncolytic polio virotherapy of cancer. Cancer. 120: 3277-86. PMID 24939611 DOI: 10.1002/cncr.28862  0.56
2014 Zhang L, Chen LH, Wan H, Yang R, Wang Z, Feng J, Yang S, Jones S, Wang S, Zhou W, Zhu H, Killela PJ, Zhang J, Wu Z, Li G, ... ... Bigner DD, et al. Exome sequencing identifies somatic gain-of-function PPM1D mutations in brainstem gliomas. Nature Genetics. 46: 726-30. PMID 24880341 DOI: 10.1038/ng.2995  0.56
2014 Babu R, Kranz PG, Agarwal V, McLendon RE, Thomas S, Friedman AH, Bigner DD, Adamson C. Malignant brainstem gliomas in adults: clinicopathological characteristics and prognostic factors. Journal of Neuro-Oncology. 119: 177-85. PMID 24838419 DOI: 10.1007/s11060-014-1471-9  0.56
2014 Miao H, Choi BD, Suryadevara CM, Sanchez-Perez L, Yang S, De Leon G, Sayour EJ, McLendon R, Herndon JE, Healy P, Archer GE, Bigner DD, Johnson LA, Sampson JH. EGFRvIII-specific chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an invasive xenograft model of glioblastoma. Plos One. 9: e94281. PMID 24722266 DOI: 10.1371/journal.pone.0094281  0.56
2014 Killela PJ, Pirozzi CJ, Healy P, Reitman ZJ, Lipp E, Rasheed BA, Yang R, Diplas BH, Wang Z, Greer PK, Zhu H, Wang CY, Carpenter AB, Friedman H, Friedman AH, ... ... Bigner DD, et al. Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas. Oncotarget. 5: 1515-25. PMID 24722048  0.56
2014 Killela PJ, Pirozzi CJ, Reitman ZJ, Jones S, Rasheed BA, Lipp E, Friedman H, Friedman AH, He Y, McLendon RE, Bigner DD, Yan H. The genetic landscape of anaplastic astrocytoma. Oncotarget. 5: 1452-7. PMID 24140581  0.56
2014 Choi BD, Suryadevara CM, Gedeon PC, Herndon JE, Sanchez-Perez L, Bigner DD, Sampson JH. Intracerebral delivery of a third generation EGFRvIII-specific chimeric antigen receptor is efficacious against human glioma. Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia. 21: 189-90. PMID 24054399 DOI: 10.1016/j.jocn.2013.03.012  0.56
2014 López GY, Grant GA, Fuchs HE, Leithe LG, Gururangan S, Bigner DD, Yan H, McLendon RE, He Y. Clinico-pathological description of three paediatric medulloblastoma cases with MLL2/3 gene mutations. Neuropathology and Applied Neurobiology. 40: 217-20. PMID 23659599 DOI: 10.1111/nan.12060  0.56
2013 Gedeon PC, Choi BD, Sampson JH, Bigner DD. Rindopepimut: anti-EGFRvIII peptide vaccine, oncolytic. Drugs of the Future. 38: 147-155. PMID 25663738 DOI: 10.1358/dof.2013.038.03.1933992  0.56
2013 Choi BD, Gedeon PC, Herndon JE, Archer GE, Reap EA, Sanchez-Perez L, Mitchell DA, Bigner DD, Sampson JH. Human regulatory T cells kill tumor cells through granzyme-dependent cytotoxicity upon retargeting with a bispecific antibody. Cancer Immunology Research. 1: 163. PMID 24570975 DOI: 10.1158/2326-6066.CIR-13-0049  0.56
2013 Chandramohan V, Bigner DD. A novel recombinant immunotoxin-based therapy targeting wild-type and mutant EGFR improves survival in murine models of glioblastoma. Oncoimmunology. 2: e26852. PMID 24498557 DOI: 10.4161/onci.26852  0.56
2013 Choi BD, Gedeon PC, Sanchez-Perez L, Bigner DD, Sampson JH. Regulatory T cells are redirected to kill glioblastoma by an EGFRvIII-targeted bispecific antibody. Oncoimmunology. 2: e26757. PMID 24475376 DOI: 10.4161/onci.26757  0.56
2013 Guo C, Chen LH, Huang Y, Chang CC, Wang P, Pirozzi CJ, Qin X, Bao X, Greer PK, McLendon RE, Yan H, Keir ST, Bigner DD, He Y. KMT2D maintains neoplastic cell proliferation and global histone H3 lysine 4 monomethylation. Oncotarget. 4: 2144-53. PMID 24240169  0.56
2013 Remke M, Ramaswamy V, Peacock J, Shih DJ, Koelsche C, Northcott PA, Hill N, Cavalli FM, Kool M, Wang X, Mack SC, Barszczyk M, Morrissy AS, Wu X, Agnihotri S, ... ... Bigner DD, et al. TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. Acta Neuropathologica. 126: 917-29. PMID 24174164 DOI: 10.1007/s00401-013-1198-2  0.56
2013 Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, Zheng S, Chakravarty D, Sanborn JZ, Berman SH, Beroukhim R, Bernard B, Wu CJ, Genovese G, Shmulevich I, ... ... Bigner DD, et al. The somatic genomic landscape of glioblastoma. Cell. 155: 462-77. PMID 24120142 DOI: 10.1016/j.cell.2013.09.034  0.56
2013 Epple LM, Dodd RD, Merz AL, Dechkovskaia AM, Herring M, Winston BA, Lencioni AM, Russell RL, Madsen H, Nega M, Dusto NL, White J, Bigner DD, Nicchitta CV, Serkova NJ, et al. Induction of the unfolded protein response drives enhanced metabolism and chemoresistance in glioma cells. Plos One. 8: e73267. PMID 24039668 DOI: 10.1371/journal.pone.0073267  0.56
2013 Gedeon PC, Choi BD, Hodges TR, Mitchell DA, Bigner DD, Sampson JH. An EGFRvIII-targeted bispecific T-cell engager overcomes limitations of the standard of care for glioblastoma. Expert Review of Clinical Pharmacology. 6: 375-86. PMID 23927666 DOI: 10.1586/17512433.2013.811806  0.56
2013 Piao H, Kuan CT, Chandramohan V, Keir ST, Pegram CN, Bao X, MÃ¥nsson JE, Pastan IH, Bigner DD. Affinity-matured recombinant immunotoxin targeting gangliosides 3'-isoLM1 and 3',6'-isoLD1 on malignant gliomas. Mabs. 5: 748-62. PMID 23924792 DOI: 10.4161/mabs.25860  0.56
2013 Frattini V, Trifonov V, Chan JM, Castano A, Lia M, Abate F, Keir ST, Ji AX, Zoppoli P, Niola F, Danussi C, Dolgalev I, Porrati P, Pellegatta S, Heguy A, ... ... Bigner DD, et al. The integrated landscape of driver genomic alterations in glioblastoma. Nature Genetics. 45: 1141-9. PMID 23917401 DOI: 10.1038/ng.2734  0.56
2013 Chandramohan V, Bao X, Keir ST, Pegram CN, Szafranski SE, Piao H, Wikstrand CJ, McLendon RE, Kuan CT, Pastan IH, Bigner DD. Construction of an immunotoxin, D2C7-(scdsFv)-PE38KDEL, targeting EGFRwt and EGFRvIII for brain tumor therapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 4717-27. PMID 23857604 DOI: 10.1158/1078-0432.CCR-12-3891  0.56
2013 Chandramohan V, Mitchell DA, Johnson LA, Sampson JH, Bigner DD. Antibody, T-cell and dendritic cell immunotherapy for malignant brain tumors. Future Oncology (London, England). 9: 977-90. PMID 23837761 DOI: 10.2217/fon.13.47  0.56
2013 Choi BD, Gedeon PC, Kuan CT, Sanchez-Perez L, Archer GE, Bigner DD, Sampson JH. Rational design and generation of recombinant control reagents for bispecific antibodies through CDR mutagenesis. Journal of Immunological Methods. 395: 14-20. PMID 23806556 DOI: 10.1016/j.jim.2013.06.003  0.56
2013 Choi BD, Pastan I, Bigner DD, Sampson JH. A novel bispecific antibody recruits T cells to eradicate tumors in the "immunologically privileged" central nervous system. Oncoimmunology. 2: e23639. PMID 23734318 DOI: 10.4161/onci.23639  0.56
2013 Sanchez-Perez L, Choi BD, Reap EA, Sayour EJ, Norberg P, Schmittling RJ, Archer GE, Herndon JE, Mitchell DA, Heimberger AB, Bigner DD, Sampson JH. BLyS levels correlate with vaccine-induced antibody titers in patients with glioblastoma lymphodepleted by therapeutic temozolomide. Cancer Immunology, Immunotherapy : Cii. 62: 983-7. PMID 23591978 DOI: 10.1007/s00262-013-1405-y  0.56
2013 Hodges TR, Choi BD, Bigner DD, Yan H, Sampson JH. Isocitrate dehydrogenase 1: what it means to the neurosurgeon: a review. Journal of Neurosurgery. 118: 1176-80. PMID 23581583 DOI: 10.3171/2013.3.JNS122282  0.56
2013 Killela PJ, Reitman ZJ, Jiao Y, Bettegowda C, Agrawal N, Diaz LA, Friedman AH, Friedman H, Gallia GL, Giovanella BC, Grollman AP, He TC, He Y, Hruban RH, Jallo GI, ... ... Bigner DD, et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proceedings of the National Academy of Sciences of the United States of America. 110: 6021-6. PMID 23530248 DOI: 10.1073/pnas.1303607110  0.56
2013 Sanchez-Perez LA, Choi BD, Archer GE, Cui X, Flores C, Johnson LA, Schmittling RJ, Snyder D, Herndon JE, Bigner DD, Mitchell DA, Sampson JH. Myeloablative temozolomide enhances CD8⁺ T-cell responses to vaccine and is required for efficacy against brain tumors in mice. Plos One. 8: e59082. PMID 23527092 DOI: 10.1371/journal.pone.0059082  0.56
2013 Poteet E, Choudhury GR, Winters A, Li W, Ryou MG, Liu R, Tang L, Ghorpade A, Wen Y, Yuan F, Keir ST, Yan H, Bigner DD, Simpkins JW, Yang SH. Reversing the Warburg effect as a treatment for glioblastoma. The Journal of Biological Chemistry. 288: 9153-64. PMID 23408428 DOI: 10.1074/jbc.M112.440354  0.56
2013 Choi BD, Kuan CT, Cai M, Archer GE, Mitchell DA, Gedeon PC, Sanchez-Perez L, Pastan I, Bigner DD, Sampson JH. Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma. Proceedings of the National Academy of Sciences of the United States of America. 110: 270-5. PMID 23248284 DOI: 10.1073/pnas.1219817110  0.56
2013 Jin G, Reitman ZJ, Duncan CG, Spasojevic I, Gooden DM, Rasheed BA, Yang R, Lopez GY, He Y, McLendon RE, Bigner DD, Yan H. Disruption of wild-type IDH1 suppresses D-2-hydroxyglutarate production in IDH1-mutated gliomas. Cancer Research. 73: 496-501. PMID 23204232 DOI: 10.1158/0008-5472.CAN-12-2852  0.56
2013 Chandramohan V, Bao X, Kato Kaneko M, Kato Y, Keir ST, Szafranski SE, Kuan CT, Pastan IH, Bigner DD. Recombinant anti-podoplanin (NZ-1) immunotoxin for the treatment of malignant brain tumors. International Journal of Cancer. Journal International Du Cancer. 132: 2339-48. PMID 23115013 DOI: 10.1002/ijc.27919  0.56
2013 Keir ST, Friedman HS, Reardon DA, Bigner DD, Gray LA. Mibefradil, a novel therapy for glioblastoma multiforme: cell cycle synchronization and interlaced therapy in a murine model. Journal of Neuro-Oncology. 111: 97-102. PMID 23086436 DOI: 10.1007/s11060-012-0995-0  0.56
2012 Shao H, Chung J, Balaj L, Charest A, Bigner DD, Carter BS, Hochberg FH, Breakefield XO, Weissleder R, Lee H. Protein typing of circulating microvesicles allows real-time monitoring of glioblastoma therapy. Nature Medicine. 18: 1835-40. PMID 23142818 DOI: 10.1038/nm.2994  0.56
2012 Guo C, Chang CC, Wortham M, Chen LH, Kernagis DN, Qin X, Cho YW, Chi JT, Grant GA, McLendon RE, Yan H, Ge K, Papadopoulos N, Bigner DD, He Y. Global identification of MLL2-targeted loci reveals MLL2's role in diverse signaling pathways. Proceedings of the National Academy of Sciences of the United States of America. 109: 17603-8. PMID 23045699 DOI: 10.1073/pnas.1208807109  0.56
2012 Reardon DA, Herndon JE, Peters KB, Desjardins A, Coan A, Lou E, Sumrall AL, Turner S, Lipp ES, Sathornsumetee S, Rich JN, Sampson JH, Friedman AH, Boulton ST, Bigner DD, et al. Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients. British Journal of Cancer. 107: 1481-7. PMID 23037712 DOI: 10.1038/bjc.2012.415  0.56
2012 Reitman ZJ, Choi BD, Spasojevic I, Bigner DD, Sampson JH, Yan H. Enzyme redesign guided by cancer-derived IDH1 mutations. Nature Chemical Biology. 8: 887-9. PMID 23001033 DOI: 10.1038/nchembio.1065  0.56
2012 Duncan CG, Barwick BG, Jin G, Rago C, Kapoor-Vazirani P, Powell DR, Chi JT, Bigner DD, Vertino PM, Yan H. A heterozygous IDH1R132H/WT mutation induces genome-wide alterations in DNA methylation. Genome Research. 22: 2339-55. PMID 22899282 DOI: 10.1101/gr.132738.111  0.56
2012 Jin G, Pirozzi CJ, Chen LH, Lopez GY, Duncan CG, Feng J, Spasojevic I, Bigner DD, He Y, Yan H. Mutant IDH1 is required for IDH1 mutated tumor cell growth. Oncotarget. 3: 774-82. PMID 22885298  0.56
2012 Gurley SN, Abidi AH, Allison P, Guan P, Duntsch C, Robertson JH, Kosanke SD, Keir ST, Bigner DD, Elberger AJ, Moore BM. Mechanism of anti-glioma activity and in vivo efficacy of the cannabinoid ligand KM-233. Journal of Neuro-Oncology. 110: 163-77. PMID 22875710 DOI: 10.1007/s11060-012-0958-5  0.56
2012 Jiao Y, Killela PJ, Reitman ZJ, Rasheed AB, Heaphy CM, de Wilde RF, Rodriguez FJ, Rosemberg S, Oba-Shinjo SM, Nagahashi Marie SK, Bettegowda C, Agrawal N, Lipp E, Pirozzi C, Lopez G, ... ... Bigner DD, et al. Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget. 3: 709-22. PMID 22869205  0.56
2012 Wortham M, Jin G, Sun JL, Bigner DD, He Y, Yan H. Aberrant Otx2 expression enhances migration and induces ectopic proliferation of hindbrain neuronal progenitor cells. Plos One. 7: e36211. PMID 22558385 DOI: 10.1371/journal.pone.0036211  0.52
2012 Chandramohan V, Sampson JH, Pastan I, Bigner DD. Toxin-based targeted therapy for malignant brain tumors. Clinical & Developmental Immunology. 2012: 480429. PMID 22400035 DOI: 10.1155/2012/480429  0.56
2012 Sampson JH, Schmittling RJ, Archer GE, Congdon KL, Nair SK, Reap EA, Desjardins A, Friedman AH, Friedman HS, Herndon JE, Coan A, McLendon RE, Reardon DA, Vredenburgh JJ, Bigner DD, et al. A pilot study of IL-2Rα blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastoma. Plos One. 7: e31046. PMID 22383993 DOI: 10.1371/journal.pone.0031046  0.56
2012 Mehta AI, Choi BD, Ajay D, Raghavan R, Brady M, Friedman AH, Pastan I, Bigner DD, Sampson JH. Convection enhanced delivery of macromolecules for brain tumors. Current Drug Discovery Technologies. 9: 305-10. PMID 22339074  0.56
2012 Marshall D, Mitchell DA, Graner MW, Bigner DD. Immunotherapy of brain tumors. Handbook of Clinical Neurology. 104: 309-30. PMID 22230450 DOI: 10.1016/B978-0-444-52138-5.00020-7  0.32
2012 Zalutsky MR, Boskovitz A, Kuan CT, Pegram CN, Ayriss J, Wikstrand CJ, Buckley AF, Lipp ES, Herndon JE, McLendon RE, Bigner DD. Radioimmunotargeting of malignant glioma by monoclonal antibody D2C7 reactive against both wild-type and variant III mutant epidermal growth factor receptors. Nuclear Medicine and Biology. 39: 23-34. PMID 21958852 DOI: 10.1016/j.nucmedbio.2011.06.005  0.56
2011 Mehta AI, Choi BD, Raghavan R, Brady M, Friedman AH, Bigner DD, Pastan I, Sampson JH. Imaging of convection enhanced delivery of toxins in humans. Toxins. 3: 201-6. PMID 22069706 DOI: 10.3390/toxins3030201  0.56
2011 Mehta AI, Kanaly CW, Friedman AH, Bigner DD, Sampson JH. Monitoring radiographic brain tumor progression. Toxins. 3: 191-200. PMID 22069705 DOI: 10.3390/toxins3030191  0.56
2011 Mitchell DA, Cui X, Schmittling RJ, Sanchez-Perez L, Snyder DJ, Congdon KL, Archer GE, Desjardins A, Friedman AH, Friedman HS, Herndon JE, McLendon RE, Reardon DA, Vredenburgh JJ, Bigner DD, et al. Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans. Blood. 118: 3003-12. PMID 21768296 DOI: 10.1182/blood-2011-02-334565  0.56
2011 Heaphy CM, de Wilde RF, Jiao Y, Klein AP, Edil BH, Shi C, Bettegowda C, Rodriguez FJ, Eberhart CG, Hebbar S, Offerhaus GJ, McLendon R, Rasheed BA, He Y, Yan H, ... Bigner DD, et al. Altered telomeres in tumors with ATRX and DAXX mutations. Science (New York, N.Y.). 333: 425. PMID 21719641 DOI: 10.1126/science.1207313  0.56
2011 Vredenburgh JJ, Desjardins A, Reardon DA, Peters KB, Herndon JE, Marcello J, Kirkpatrick JP, Sampson JH, Bailey L, Threatt S, Friedman AH, Bigner DD, Friedman HS. The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 4119-24. PMID 21531816 DOI: 10.1158/1078-0432.CCR-11-0120  0.56
2011 Davis F, Il'yasova D, Rankin K, McCarthy B, Bigner DD. Medical diagnostic radiation exposures and risk of gliomas. Radiation Research. 175: 790-6. PMID 21466382 DOI: 10.1667/RR2186.1  0.56
2011 Reardon DA, Turner S, Peters KB, Desjardins A, Gururangan S, Sampson JH, McLendon RE, Herndon JE, Jones LW, Kirkpatrick JP, Friedman AH, Vredenburgh JJ, Bigner DD, Friedman HS. A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma. Journal of the National Comprehensive Cancer Network : Jnccn. 9: 414-27. PMID 21464146  0.56
2011 Choi BD, Cai M, Bigner DD, Mehta AI, Kuan CT, Sampson JH. Bispecific antibodies engage T cells for antitumor immunotherapy. Expert Opinion On Biological Therapy. 11: 843-53. PMID 21449821 DOI: 10.1517/14712598.2011.572874  0.56
2011 Sampson JH, Brady M, Raghavan R, Mehta AI, Friedman AH, Reardon DA, Petry NA, Barboriak DP, Wong TZ, Zalutsky MR, Lally-Goss D, Bigner DD. Colocalization of gadolinium-diethylene triamine pentaacetic acid with high-molecular-weight molecules after intracerebral convection-enhanced delivery in humans. Neurosurgery. 69: 668-76. PMID 21430586 DOI: 10.1227/NEU.0b013e3182181ba8  0.56
2011 Jin G, Reitman ZJ, Spasojevic I, Batinic-Haberle I, Yang J, Schmidt-Kittler O, Bigner DD, Yan H. 2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutations. Plos One. 6: e16812. PMID 21326614 DOI: 10.1371/journal.pone.0016812  0.52
2011 McCarthy BJ, Rankin K, Il'yasova D, Erdal S, Vick N, Ali-Osman F, Bigner DD, Davis F. Assessment of type of allergy and antihistamine use in the development of glioma. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 20: 370-8. PMID 21300619 DOI: 10.1158/1055-9965.EPI-10-0948  0.56
2011 Kanaly CW, Ding D, Mehta AI, Waller AF, Crocker I, Desjardins A, Reardon DA, Friedman AH, Bigner DD, Sampson JH. A novel method for volumetric MRI response assessment of enhancing brain tumors. Plos One. 6: e16031. PMID 21298088 DOI: 10.1371/journal.pone.0016031  0.56
2011 Reitman ZJ, Jin G, Karoly ED, Spasojevic I, Yang J, Kinzler KW, He Y, Bigner DD, Vogelstein B, Yan H. Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome. Proceedings of the National Academy of Sciences of the United States of America. 108: 3270-5. PMID 21289278 DOI: 10.1073/pnas.1019393108  0.56
2011 Parsons DW, Li M, Zhang X, Jones S, Leary RJ, Lin JC, Boca SM, Carter H, Samayoa J, Bettegowda C, Gallia GL, Jallo GI, Binder ZA, Nikolsky Y, Hartigan J, ... ... Bigner DD, et al. The genetic landscape of the childhood cancer medulloblastoma. Science (New York, N.Y.). 331: 435-9. PMID 21163964 DOI: 10.1126/science.1198056  0.56
2011 Sampson JH, Aldape KD, Archer GE, Coan A, Desjardins A, Friedman AH, Friedman HS, Gilbert MR, Herndon JE, McLendon RE, Mitchell DA, Reardon DA, Sawaya R, Schmittling R, Shi W, ... ... Bigner DD, et al. Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. Neuro-Oncology. 13: 324-33. PMID 21149254 DOI: 10.1093/neuonc/noq157  0.56
2011 Kuan CT, Wakiya K, Keir ST, Li J, Herndon JE, Pastan I, Bigner DD. Affinity-matured anti-glycoprotein NMB recombinant immunotoxins targeting malignant gliomas and melanomas. International Journal of Cancer. Journal International Du Cancer. 129: 111-21. PMID 20824708 DOI: 10.1002/ijc.25645  0.56
2011 Reardon DA, Vredenburgh JJ, Desjardins A, Peters K, Gururangan S, Sampson JH, Marcello J, Herndon JE, McLendon RE, Janney D, Friedman AH, Bigner DD, Friedman HS. Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma. Journal of Neuro-Oncology. 101: 57-66. PMID 20443129 DOI: 10.1007/s11060-010-0217-6  0.56
2010 Cui B, Johnson SP, Bullock N, Ali-Osman F, Bigner DD, Friedman HS. Decoupling of DNA damage response signaling from DNA damages underlies temozolomide resistance in glioblastoma cells. Journal of Biomedical Research. 24: 424-35. PMID 23554659 DOI: 10.1016/S1674-8301(10)60057-7  0.56
2010 Adamson DC, Rasheed BA, McLendon RE, Bigner DD. Central nervous system. Cancer Biomarkers : Section a of Disease Markers. 9: 193-210. PMID 22112477 DOI: 10.3233/CBM-2011-0177  0.56
2010 Duncan CG, Killela PJ, Payne CA, Lampson B, Chen WC, Liu J, Solomon D, Waldman T, Towers AJ, Gregory SG, McDonald KL, McLendon RE, Bigner DD, Yan H. Integrated genomic analyses identify ERRFI1 and TACC3 as glioblastoma-targeted genes. Oncotarget. 1: 265-77. PMID 21113414  0.56
2010 Kuan CT, Chang J, Mansson JE, Li J, Pegram C, Fredman P, McLendon RE, Bigner DD. Multiple phenotypic changes in mice after knockout of the B3gnt5 gene, encoding Lc3 synthase--a key enzyme in lacto-neolacto ganglioside synthesis. Bmc Developmental Biology. 10: 114. PMID 21087515 DOI: 10.1186/1471-213X-10-114  0.56
2010 Sampson JH, Heimberger AB, Archer GE, Aldape KD, Friedman AH, Friedman HS, Gilbert MR, Herndon JE, McLendon RE, Mitchell DA, Reardon DA, Sawaya R, Schmittling RJ, Shi W, Vredenburgh JJ, ... Bigner DD, et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 4722-9. PMID 20921459 DOI: 10.1200/JCO.2010.28.6963  0.56
2010 Kato Y, Vaidyanathan G, Kaneko MK, Mishima K, Srivastava N, Chandramohan V, Pegram C, Keir ST, Kuan CT, Bigner DD, Zalutsky MR. Evaluation of anti-podoplanin rat monoclonal antibody NZ-1 for targeting malignant gliomas. Nuclear Medicine and Biology. 37: 785-94. PMID 20870153 DOI: 10.1016/j.nucmedbio.2010.03.010  0.56
2010 Hens M, Vaidyanathan G, Zhao XG, Bigner DD, Zalutsky MR. Anti-EGFRvIII monoclonal antibody armed with 177Lu: in vivo comparison of macrocyclic and acyclic ligands. Nuclear Medicine and Biology. 37: 741-50. PMID 20870149 DOI: 10.1016/j.nucmedbio.2010.04.020  0.48
2010 Kuan CT, Wakiya K, Herndon JE, Lipp ES, Pegram CN, Riggins GJ, Rasheed A, Szafranski SE, McLendon RE, Wikstrand CJ, Bigner DD. MRP3: a molecular target for human glioblastoma multiforme immunotherapy. Bmc Cancer. 10: 468. PMID 20809959 DOI: 10.1186/1471-2407-10-468  0.56
2010 Wheeler SE, Suzuki S, Thomas SM, Sen M, Leeman-Neill RJ, Chiosea SI, Kuan CT, Bigner DD, Gooding WE, Lai SY, Grandis JR. Epidermal growth factor receptor variant III mediates head and neck cancer cell invasion via STAT3 activation. Oncogene. 29: 5135-45. PMID 20622897 DOI: 10.1038/onc.2009.279  0.56
2010 Lopez GY, Reitman ZJ, Solomon D, Waldman T, Bigner DD, McLendon RE, Rosenberg SA, Samuels Y, Yan H. IDH1(R132) mutation identified in one human melanoma metastasis, but not correlated with metastases to the brain. Biochemical and Biophysical Research Communications. 398: 585-7. PMID 20603105 DOI: 10.1016/j.bbrc.2010.06.125  0.56
2010 Jin G, Cook S, Cui B, Chen WC, Keir ST, Killela P, Di C, Payne CA, Gregory SG, McLendon R, Bigner DD, Yan H. HDMX regulates p53 activity and confers chemoresistance to 3-bis(2-chloroethyl)-1-nitrosourea. Neuro-Oncology. 12: 956-66. PMID 20472715 DOI: 10.1093/neuonc/noq045  0.56
2010 Adamson DC, Shi Q, Wortham M, Northcott PA, Di C, Duncan CG, Li J, McLendon RE, Bigner DD, Taylor MD, Yan H. OTX2 is critical for the maintenance and progression of Shh-independent medulloblastomas. Cancer Research. 70: 181-91. PMID 20028867 DOI: 10.1158/0008-5472.CAN-09-2331  0.56
2010 Kato Y, Kuan CT, Chang J, Kaneko MK, Ayriss J, Piao H, Chandramohan V, Pegram C, McLendon RE, Fredman P, MÃ¥nsson JE, Bigner DD. GMab-1, a high-affinity anti-3'-isoLM1/3',6'-isoLD1 IgG monoclonal antibody, raised in lacto-series ganglioside-defective knockout mice. Biochemical and Biophysical Research Communications. 391: 750-5. PMID 19944071 DOI: 10.1016/j.bbrc.2009.11.132  0.56
2010 Kuan CT, Srivastava N, McLendon RE, Marasco WA, Zalutsky MR, Bigner DD. Recombinant single-chain variable fragment antibodies against extracellular epitopes of human multidrug resistance protein MRP3 for targeting malignant gliomas. International Journal of Cancer. Journal International Du Cancer. 127: 598-611. PMID 19937796 DOI: 10.1002/ijc.25062  0.56
2010 Ding D, Kanaly CW, Bigner DD, Cummings TJ, Herndon JE, Pastan I, Raghavan R, Sampson JH. Convection-enhanced delivery of free gadolinium with the recombinant immunotoxin MR1-1. Journal of Neuro-Oncology. 98: 1-7. PMID 19898744 DOI: 10.1007/s11060-009-0046-7  0.56
2010 Reitman ZJ, Olby NJ, Mariani CL, Thomas R, Breen M, Bigner DD, McLendon RE, Yan H. IDH1 and IDH2 hotspot mutations are not found in canine glioma. International Journal of Cancer. Journal International Du Cancer. 127: 245-6. PMID 19877121 DOI: 10.1002/ijc.25017  0.56
2009 Kuan CT, Wikstrand CJ, McLendon RE, Zalutsky MR, Kumar U, Bigner DD. Detection of amino-terminal extracellular domain of somatostatin receptor 2 by specific monoclonal antibodies and quantification of receptor density in medulloblastoma. Hybridoma (2005). 28: 389-403. PMID 20025498 DOI: 10.1089/hyb.2009.0049  0.56
2009 Yan H, Bigner DD, Velculescu V, Parsons DW. Mutant metabolic enzymes are at the origin of gliomas. Cancer Research. 69: 9157-9. PMID 19996293 DOI: 10.1158/0008-5472.CAN-09-2650  0.52
2009 Reardon DA, Desjardins A, Vredenburgh JJ, Gururangan S, Sampson JH, Sathornsumetee S, McLendon RE, Herndon JE, Marcello JE, Norfleet J, Friedman AH, Bigner DD, Friedman HS. Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study. British Journal of Cancer. 101: 1986-94. PMID 19920819 DOI: 10.1038/sj.bjc.6605412  0.56
2009 Lu Z, Zhou L, Killela P, Rasheed AB, Di C, Poe WE, McLendon RE, Bigner DD, Nicchitta C, Yan H. Glioblastoma proto-oncogene SEC61gamma is required for tumor cell survival and response to endoplasmic reticulum stress. Cancer Research. 69: 9105-11. PMID 19920201 DOI: 10.1158/0008-5472.CAN-09-2775  0.56
2009 Sampson JH, Archer GE, Mitchell DA, Heimberger AB, Herndon JE, Lally-Goss D, McGehee-Norman S, Paolino A, Reardon DA, Friedman AH, Friedman HS, Bigner DD. An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme. Molecular Cancer Therapeutics. 8: 2773-9. PMID 19825799 DOI: 10.1158/1535-7163.MCT-09-0124  0.56
2009 Kato Y, Jin G, Kuan CT, McLendon RE, Yan H, Bigner DD. A monoclonal antibody IMab-1 specifically recognizes IDH1R132H, the most common glioma-derived mutation. Biochemical and Biophysical Research Communications. 390: 547-51. PMID 19818334 DOI: 10.1016/j.bbrc.2009.10.001  0.56
2009 Kanu OO, Hughes B, Di C, Lin N, Fu J, Bigner DD, Yan H, Adamson C. Glioblastoma Multiforme Oncogenomics and Signaling Pathways. Clinical Medicine. Oncology. 3: 39-52. PMID 19777070  0.52
2009 Choi BD, Archer GE, Mitchell DA, Heimberger AB, McLendon RE, Bigner DD, Sampson JH. EGFRvIII-targeted vaccination therapy of malignant glioma. Brain Pathology (Zurich, Switzerland). 19: 713-23. PMID 19744042 DOI: 10.1111/j.1750-3639.2009.00318.x  0.56
2009 Graner MW, Raynes DA, Bigner DD, Guerriero V. Heat shock protein 70-binding protein 1 is highly expressed in high-grade gliomas, interacts with multiple heat shock protein 70 family members, and specifically binds brain tumor cell surfaces. Cancer Science. 100: 1870-9. PMID 19659607 DOI: 10.1111/j.1349-7006.2009.01269.x  0.32
2009 Boskovitz A, McLendon RE, Okamura T, Sampson JH, Bigner DD, Zalutsky MR. Treatment of HER2-positive breast carcinomatous meningitis with intrathecal administration of alpha-particle-emitting (211)At-labeled trastuzumab. Nuclear Medicine and Biology. 36: 659-69. PMID 19647172 DOI: 10.1016/j.nucmedbio.2009.04.003  0.56
2009 Bektas M, Johnson SP, Poe WE, Bigner DD, Friedman HS. A sphingosine kinase inhibitor induces cell death in temozolomide resistant glioblastoma cells. Cancer Chemotherapy and Pharmacology. 64: 1053-8. PMID 19597728 DOI: 10.1007/s00280-009-1063-0  0.56
2009 Adamson C, Kanu OO, Mehta AI, Di C, Lin N, Mattox AK, Bigner DD. Glioblastoma multiforme: a review of where we have been and where we are going. Expert Opinion On Investigational Drugs. 18: 1061-83. PMID 19555299 DOI: 10.1517/13543780903052764  0.32
2009 Affronti ML, Heery CR, Herndon JE, Rich JN, Reardon DA, Desjardins A, Vredenburgh JJ, Friedman AH, Bigner DD, Friedman HS. Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy. Cancer. 115: 3501-11. PMID 19514083 DOI: 10.1002/cncr.24398  0.56
2009 Il'yasova D, McCarthy BJ, Erdal S, Shimek J, Goldstein J, Doerge DR, Myers SR, Vineis P, Wishnok JS, Swenberg JA, Bigner DD, Davis FG. Human exposure to selected animal neurocarcinogens: a biomarker-based assessment and implications for brain tumor epidemiology. Journal of Toxicology and Environmental Health. Part B, Critical Reviews. 12: 175-87. PMID 19466671 DOI: 10.1080/10937400902894152  0.56
2009 Kanu OO, Mehta A, Di C, Lin N, Bortoff K, Bigner DD, Yan H, Adamson DC. Glioblastoma multiforme: a review of therapeutic targets. Expert Opinion On Therapeutic Targets. 13: 701-18. PMID 19409033 DOI: 10.1517/14728220902942348  0.56
2009 Il'yasova D, McCarthy B, Marcello J, Schildkraut JM, Moorman PG, Krishnamachari B, Ali-Osman F, Bigner DD, Davis F. Association between glioma and history of allergies, asthma, and eczema: a case-control study with three groups of controls. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 18: 1232-8. PMID 19336556 DOI: 10.1158/1055-9965.EPI-08-0995  0.56
2009 Quinn JA, Jiang SX, Reardon DA, Desjardins A, Vredenburgh JJ, Rich JN, Gururangan S, Friedman AH, Bigner DD, Sampson JH, McLendon RE, Herndon JE, Walker A, Friedman HS. Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma. Neuro-Oncology. 11: 556-61. PMID 19289491 DOI: 10.1215/15228517-2009-007  0.56
2009 Cui B, Johnson SP, Bullock N, Ali-Osman F, Bigner DD, Friedman HS. Bifunctional DNA alkylator 1,3-bis(2-chloroethyl)-1-nitrosourea activates the ATR-Chk1 pathway independently of the mismatch repair pathway. Molecular Pharmacology. 75: 1356-63. PMID 19261750 DOI: 10.1124/mol.108.053124  0.56
2009 Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, Friedman H, Friedman A, Reardon D, Herndon J, Kinzler KW, ... ... Bigner DD, et al. IDH1 and IDH2 mutations in gliomas. The New England Journal of Medicine. 360: 765-73. PMID 19228619 DOI: 10.1056/NEJMoa0808710  0.56
2009 Quinn JA, Jiang SX, Reardon DA, Desjardins A, Vredenburgh JJ, Rich JN, Gururangan S, Friedman AH, Bigner DD, Sampson JH, McLendon RE, Herndon JE, Walker A, Friedman HS. Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 1262-7. PMID 19204199 DOI: 10.1200/JCO.2008.18.8417  0.56
2009 Quinn JA, Jiang SX, Carter J, Reardon DA, Desjardins A, Vredenburgh JJ, Rich JN, Gururangan S, Friedman AH, Bigner DD, Sampson JH, McLendon RE, Herndon JE, Threatt S, Friedman HS. Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 1064-8. PMID 19188181 DOI: 10.1158/1078-0432.CCR-08-2130  0.56
2009 Graner MW, Alzate O, Dechkovskaia AM, Keene JD, Sampson JH, Mitchell DA, Bigner DD. Proteomic and immunologic analyses of brain tumor exosomes. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 23: 1541-57. PMID 19109410 DOI: 10.1096/fj.08-122184  0.56
2009 Liu Y, Kuan CT, Mi J, Zhang X, Clary BM, Bigner DD, Sullenger BA. Aptamers selected against the unglycosylated EGFRvIII ectodomain and delivered intracellularly reduce membrane-bound EGFRvIII and induce apoptosis. Biological Chemistry. 390: 137-44. PMID 19040357 DOI: 10.1515/BC.2009.022  0.36
2009 Bacolod MD, Fehdrau R, Johnson SP, Bullock NS, Bigner DD, Colvin M, Friedman HS. BCNU-sequestration by metallothioneins may contribute to resistance in a medulloblastoma cell line. Cancer Chemotherapy and Pharmacology. 63: 753-8. PMID 18633619 DOI: 10.1007/s00280-008-0792-9  0.56
2008 Desjardins A, Reardon DA, Herndon JE, Marcello J, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Bailey L, Bigner DD, Friedman AH, Friedman HS, Vredenburgh JJ. Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 7068-73. PMID 18981004 DOI: 10.1158/1078-0432.CCR-08-0260  0.56
2008 Schmittling RJ, Archer GE, Mitchell DA, Heimberger A, Pegram C, Herndon JE, Friedman HS, Bigner DD, Sampson JH. Detection of humoral response in patients with glioblastoma receiving EGFRvIII-KLH vaccines. Journal of Immunological Methods. 339: 74-81. PMID 18775433 DOI: 10.1016/j.jim.2008.08.004  0.56
2008 Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, Olivi A, McLendon R, Rasheed BA, Keir S, Nikolskaya T, ... ... Bigner DD, et al. An integrated genomic analysis of human glioblastoma multiforme. Science (New York, N.Y.). 321: 1807-12. PMID 18772396 DOI: 10.1126/science.1164382  0.56
2008 Maxwell JA, Johnson SP, McLendon RE, Lister DW, Horne KS, Rasheed A, Quinn JA, Ali-Osman F, Friedman AH, Modrich PL, Bigner DD, Friedman HS. Mismatch repair deficiency does not mediate clinical resistance to temozolomide in malignant glioma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 4859-68. PMID 18676759 DOI: 10.1158/1078-0432.CCR-07-4807  0.56
2008 Sampson JH, Archer GE, Mitchell DA, Heimberger AB, Bigner DD. Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma. Seminars in Immunology. 20: 267-75. PMID 18539480 DOI: 10.1016/j.smim.2008.04.001  0.56
2008 Bacolod MD, Lin SM, Johnson SP, Bullock NS, Colvin M, Bigner DD, Friedman HS. The gene expression profiles of medulloblastoma cell lines resistant to preactivated cyclophosphamide. Current Cancer Drug Targets. 8: 172-9. PMID 18473730 DOI: 10.2174/156800908784293631  0.56
2008 Everson RG, Graner MW, Gromeier M, Vredenburgh JJ, Desjardins A, Reardon DA, Friedman HS, Friedman AH, Bigner DD, Sampson JH. Immunotherapy against angiogenesis-associated targets: evidence and implications for the treatment of malignant glioma. Expert Review of Anticancer Therapy. 8: 717-32. PMID 18471045 DOI: 10.1586/14737140.8.5.717  0.56
2008 Sampson JH, Akabani G, Archer GE, Berger MS, Coleman RE, Friedman AH, Friedman HS, Greer K, Herndon JE, Kunwar S, McLendon RE, Paolino A, Petry NA, Provenzale JM, Reardon DA, ... ... Bigner DD, et al. Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors. Neuro-Oncology. 10: 320-9. PMID 18403491 DOI: 10.1215/15228517-2008-012  0.56
2008 Reardon DA, Zalutsky MR, Akabani G, Coleman RE, Friedman AH, Herndon JE, McLendon RE, Pegram CN, Quinn JA, Rich JN, Vredenburgh JJ, Desjardins A, Guruangan S, Boulton S, Raynor RH, ... ... Bigner DD, et al. A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost. Neuro-Oncology. 10: 182-9. PMID 18287339 DOI: 10.1215/15228517-2007-053  0.56
2008 Mott RT, Turner KC, Bigner DD, McLendon RE. Utility of EGFR and PTEN numerical aberrations in the evaluation of diffusely infiltrating astrocytomas. Laboratory investigation. Journal of Neurosurgery. 108: 330-5. PMID 18240930 DOI: 10.3171/JNS/2008/108/2/0330  0.56
2008 Yoshimoto K, Dang J, Zhu S, Nathanson D, Huang T, Dumont R, Seligson DB, Yong WH, Xiong Z, Rao N, Winther H, Chakravarti A, Bigner DD, Mellinghoff IK, Horvath S, et al. Development of a real-time RT-PCR assay for detecting EGFRvIII in glioblastoma samples. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 488-93. PMID 18223223 DOI: 10.1158/1078-0432.CCR-07-1966  0.56
2008 Heimberger AB, Sun W, Hussain SF, Dey M, Crutcher L, Aldape K, Gilbert M, Hassenbusch SJ, Sawaya R, Schmittling B, Archer GE, Mitchell DA, Bigner DD, Sampson JH. Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study. Neuro-Oncology. 10: 98-103. PMID 18079360 DOI: 10.1215/15228517-2007-046  0.56
2008 Zalutsky MR, Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, McLendon RE, Wong TZ, Bigner DD. Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 49: 30-8. PMID 18077533 DOI: 10.2967/jnumed.107.046938  0.56
2008 Ochiai H, Archer GE, Herndon JE, Kuan CT, Mitchell DA, Bigner DD, Pastan IH, Sampson JH. EGFRvIII-targeted immunotoxin induces antitumor immunity that is inhibited in the absence of CD4+ and CD8+ T cells. Cancer Immunology, Immunotherapy : Cii. 57: 115-21. PMID 17634939 DOI: 10.1007/s00262-007-0363-7  0.56
2007 Vredenburgh JJ, Desjardins A, Herndon JE, Marcello J, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Wagner M, Bailey L, Bigner DD, Friedman AH, Friedman HS. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 25: 4722-9. PMID 17947719 DOI: 10.1200/JCO.2007.12.2440  0.56
2007 Graner MW, Cumming RI, Bigner DD. The heat shock response and chaperones/heat shock proteins in brain tumors: surface expression, release, and possible immune consequences. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 27: 11214-27. PMID 17942716 DOI: 10.1523/JNEUROSCI.3588-07.2007  0.32
2007 Zalutsky MR, Reardon DA, Pozzi OR, Vaidyanathan G, Bigner DD. Targeted alpha-particle radiotherapy with 211At-labeled monoclonal antibodies. Nuclear Medicine and Biology. 34: 779-85. PMID 17921029 DOI: 10.1016/j.nucmedbio.2007.03.007  0.48
2007 Hjelmeland AB, Lattimore KP, Fee BE, Shi Q, Wickman S, Keir ST, Hjelmeland MD, Batt D, Bigner DD, Friedman HS, Rich JN. The combination of novel low molecular weight inhibitors of RAF (LBT613) and target of rapamycin (RAD001) decreases glioma proliferation and invasion. Molecular Cancer Therapeutics. 6: 2449-57. PMID 17766837 DOI: 10.1158/1535-7163.MCT-07-0155  0.56
2007 Badruddoja MA, Keir ST, King I, Zeidner J, Vredenburgh JJ, Muhlbaier LH, Bigner DD, Friedman HS. Activity of VNP40101M (Cloretazine) in the treatment of CNS tumor xenografts in athymic mice. Neuro-Oncology. 9: 240-4. PMID 17522334 DOI: 10.1215/15228517-2007-011  0.56
2007 McLendon RE, Akabani G, Friedman HS, Reardon DA, Cleveland L, Cokgor I, Herndon JE, Wikstrand C, Boulton ST, Friedman AH, Bigner DD, Zalutsky MR. Tumor resection cavity administered iodine-131-labeled antitenascin 81C6 radioimmunotherapy in patients with malignant glioma: neuropathology aspects. Nuclear Medicine and Biology. 34: 405-13. PMID 17499730 DOI: 10.1016/j.nucmedbio.2007.01.009  0.56
2007 Reardon DA, Zalutsky MR, Bigner DD. Antitenascin-C monoclonal antibody radioimmunotherapy for malignant glioma patients. Expert Review of Anticancer Therapy. 7: 675-87. PMID 17492931 DOI: 10.1586/14737140.7.5.675  0.48
2007 Sampson JH, Raghavan R, Brady ML, Provenzale JM, Herndon JE, Croteau D, Friedman AH, Reardon DA, Coleman RE, Wong T, Bigner DD, Pastan I, Rodríguez-Ponce MI, Tanner P, Puri R, et al. Clinical utility of a patient-specific algorithm for simulating intracerebral drug infusions. Neuro-Oncology. 9: 343-53. PMID 17435179 DOI: 10.1215/15228517-2007-007  0.56
2007 Fecci PE, Ochiai H, Mitchell DA, Grossi PM, Sweeney AE, Archer GE, Cummings T, Allison JP, Bigner DD, Sampson JH. Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 2158-67. PMID 17404100 DOI: 10.1158/1078-0432.CCR-06-2070  0.56
2007 Johnson SP, Kamen BA, Bigner DD, Friedman HS. O (4)-benzylfolic acid inactivates O (6)-alkylguanine-DNA alkyltransferase in brain tumor cell lines. Cancer Chemotherapy and Pharmacology. 60: 883-9. PMID 17333191 DOI: 10.1007/s00280-007-0435-6  0.56
2007 Vredenburgh JJ, Desjardins A, Herndon JE, Dowell JM, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Wagner M, Bigner DD, Friedman AH, Friedman HS. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 1253-9. PMID 17317837 DOI: 10.1158/1078-0432.CCR-06-2309  0.56
2007 Yordanov AT, Hens M, Pegram C, Bigner DD, Zalutsky MR. Antitenascin antibody 81C6 armed with 177Lu: in vivo comparison of macrocyclic and acyclic ligands. Nuclear Medicine and Biology. 34: 173-83. PMID 17307125 DOI: 10.1016/j.nucmedbio.2006.11.003  0.48
2007 Sampson JH, Brady ML, Petry NA, Croteau D, Friedman AH, Friedman HS, Wong T, Bigner DD, Pastan I, Puri RK, Pedain C. Intracerebral infusate distribution by convection-enhanced delivery in humans with malignant gliomas: descriptive effects of target anatomy and catheter positioning. Neurosurgery. 60: ONS89-98; discussion. PMID 17297371 DOI: 10.1227/01.NEU.0000249256.09289.5F  0.56
2007 Shi Q, Hjelmeland AB, Keir ST, Song L, Wickman S, Jackson D, Ohmori O, Bigner DD, Friedman HS, Rich JN. A novel low-molecular weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth. Molecular Carcinogenesis. 46: 488-96. PMID 17219439 DOI: 10.1002/mc.20297  0.56
2007 Shi Q, Bao S, Song L, Wu Q, Bigner DD, Hjelmeland AB, Rich JN. Targeting SPARC expression decreases glioma cellular survival and invasion associated with reduced activities of FAK and ILK kinases. Oncogene. 26: 4084-94. PMID 17213807 DOI: 10.1038/sj.onc.1210181  0.56
2007 Badruddoja MA, Penne K, Desjardins A, Reardon DA, Rich JN, Quinn JA, Sathornsumetee S, Friedman AH, Bigner DD, Herndon JE, Cahill A, Friedman HS, Vredenburgh JJ. Phase II study of Cloretazine for the treatment of adults with recurrent glioblastoma multiforme. Neuro-Oncology. 9: 70-4. PMID 17108065 DOI: 10.1215/15228517-2006-022  0.56
2007 Jones LW, Guill B, Keir ST, Carter K, Friedman HS, Bigner DD, Reardon DA. Using the theory of planned behavior to understand the determinants of exercise intention in patients diagnosed with primary brain cancer. Psycho-Oncology. 16: 232-40. PMID 16929468 DOI: 10.1002/pon.1077  0.56
2007 Jones LW, Guill B, Keir ST, Carter K, Friedman HS, Bigner DD, Reardon DA. Exercise interest and preferences among patients diagnosed with primary brain cancer. Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer. 15: 47-55. PMID 16819629 DOI: 10.1007/s00520-006-0096-8  0.56
2006 Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, Rich JN. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 444: 756-60. PMID 17051156 DOI: 10.1038/nature05236  0.56
2006 Maxwell JA, Johnson SP, Quinn JA, McLendon RE, Ali-Osman F, Friedman AH, Herndon JE, Bierau K, Bigley J, Bigner DD, Friedman HS. Quantitative analysis of O6-alkylguanine-DNA alkyltransferase in malignant glioma. Molecular Cancer Therapeutics. 5: 2531-9. PMID 17041097 DOI: 10.1158/1535-7163.MCT-06-0106  0.56
2006 Sok JC, Coppelli FM, Thomas SM, Lango MN, Xi S, Hunt JL, Freilino ML, Graner MW, Wikstrand CJ, Bigner DD, Gooding WE, Furnari FB, Grandis JR. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 5064-73. PMID 16951222 DOI: 10.1158/1078-0432.CCR-06-0913  0.56
2006 Sathornsumetee S, Hjelmeland AB, Keir ST, McLendon RE, Batt D, Ramsey T, Yusuff N, Rasheed BK, Kieran MW, Laforme A, Bigner DD, Friedman HS, Rich JN. AAL881, a novel small molecule inhibitor of RAF and vascular endothelial growth factor receptor activities, blocks the growth of malignant glioma. Cancer Research. 66: 8722-30. PMID 16951188 DOI: 10.1158/0008-5472.CAN-06-0284  0.56
2006 Bao S, Wu Q, Sathornsumetee S, Hao Y, Li Z, Hjelmeland AB, Shi Q, McLendon RE, Bigner DD, Rich JN. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Research. 66: 7843-8. PMID 16912155 DOI: 10.1158/0008-5472.CAN-06-1010  0.56
2006 Fecci PE, Sweeney AE, Grossi PM, Nair SK, Learn CA, Mitchell DA, Cui X, Cummings TJ, Bigner DD, Gilboa E, Sampson JH. Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 4294-305. PMID 16857805 DOI: 10.1158/1078-0432.CCR-06-0053  0.56
2006 Vaidyanathan G, Alston KL, Bigner DD, Zalutsky MR. Nepsilon-(3-[*I]Iodobenzoyl)-Lys5-Nalpha-maleimido-Gly1-GEEEK ([*I]IB-Mal-D-GEEEK): a radioiodinated prosthetic group containing negatively charged D-glutamates for labeling internalizing monoclonal antibodies. Bioconjugate Chemistry. 17: 1085-92. PMID 16848419 DOI: 10.1021/bc0600766  0.56
2006 Graner MW, Bigner DD. Therapeutic aspects of chaperones/heat-shock proteins in neuro-oncology. Expert Review of Anticancer Therapy. 6: 679-95. PMID 16759160 DOI: 10.1586/14737140.6.5.679  0.32
2006 Reardon DA, Quinn JA, Akabani G, Coleman RE, Friedman AH, Friedman HS, Herndon JE, McLendon RE, Pegram CN, Provenzale JM, Dowell JM, Rich JN, Vredenburgh JJ, Desjardins A, Sampson JH, ... ... Bigner DD, et al. Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial results. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 47: 912-8. PMID 16741299  0.56
2006 Kuan CT, Wakiya K, Dowell JM, Herndon JE, Reardon DA, Graner MW, Riggins GJ, Wikstrand CJ, Bigner DD. Glycoprotein nonmetastatic melanoma protein B, a potential molecular therapeutic target in patients with glioblastoma multiforme. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 1970-82. PMID 16609006 DOI: 10.1158/1078-0432.CCR-05-2797  0.52
2006 Jones LW, Guill B, Keir ST, Carter B S K, Friedman HS, Bigner DD, Reardon DA. Patterns of exercise across the cancer trajectory in brain tumor patients. Cancer. 106: 2224-32. PMID 16586497 DOI: 10.1002/cncr.21858  0.56
2006 Fecci PE, Mitchell DA, Whitesides JF, Xie W, Friedman AH, Archer GE, Herndon JE, Bigner DD, Dranoff G, Sampson JH. Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Research. 66: 3294-302. PMID 16540683 DOI: 10.1158/0008-5472.CAN-05-3773  0.56
2006 Reardon DA, Rich JN, Friedman HS, Bigner DD. Recent advances in the treatment of malignant astrocytoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 1253-65. PMID 16525180 DOI: 10.1200/JCO.2005.04.5302  0.56
2006 Reardon DA, Quinn JA, Vredenburgh JJ, Gururangan S, Friedman AH, Desjardins A, Sathornsumetee S, Herndon JE, Dowell JM, McLendon RE, Provenzale JM, Sampson JH, Smith RP, Swaisland AJ, Ochs JS, ... ... Bigner DD, et al. Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 860-8. PMID 16467100 DOI: 10.1158/1078-0432.CCR-05-2215  0.56
2006 Shankar S, Vaidyanathan G, Kuan CT, Bigner DD, Zalutsky MR. Antiepidermal growth factor variant III scFv fragment: effect of radioiodination method on tumor targeting and normal tissue clearance. Nuclear Medicine and Biology. 33: 101-10. PMID 16459265 DOI: 10.1016/j.nucmedbio.2005.08.004  0.48
2006 Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, Herndon JE, McLendon RE, Pegram CN, Provenzale JM, Quinn JA, Rich JN, Vredenburgh JJ, Desjardins A, Gururangan S, Guruangan S, ... ... Bigner DD, et al. Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 115-22. PMID 16382120 DOI: 10.1200/JCO.2005.03.4082  0.56
2005 Hjelmeland AB, Hjelmeland MD, Shi Q, Hart JL, Bigner DD, Wang XF, Kontos CD, Rich JN. Loss of phosphatase and tensin homologue increases transforming growth factor beta-mediated invasion with enhanced SMAD3 transcriptional activity. Cancer Research. 65: 11276-81. PMID 16357132 DOI: 10.1158/0008-5472.CAN-05-3016  0.56
2005 Rich JN, Sathornsumetee S, Keir ST, Kieran MW, Laforme A, Kaipainen A, McLendon RE, Graner MW, Rasheed BK, Wang L, Reardon DA, Ryan AJ, Wheeler C, Dimery I, Bigner DD, et al. ZD6474, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor, inhibits tumor growth of multiple nervous system tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 8145-57. PMID 16299247 DOI: 10.1158/1078-0432.CCR-05-0319  0.56
2005 Friedman HS, Bigner DD. Glioblastoma multiforme and the epidermal growth factor receptor. The New England Journal of Medicine. 353: 1997-9. PMID 16282174 DOI: 10.1056/NEJMp058186  0.56
2005 Chang SM, Reynolds SL, Butowski N, Lamborn KR, Buckner JC, Kaplan RS, Bigner DD. GNOSIS: guidelines for neuro-oncology: standards for investigational studies-reporting of phase 1 and phase 2 clinical trials. Neuro-Oncology. 7: 425-34. PMID 16212807 DOI: 10.1215/S1152851705000554  0.56
2005 Rizzieri DA, Wadleigh M, Wikstrand CJ, Mann KP, Sen F, Peterson BL, Niedzwiecki D, Proia AD, Bigner DD. Tenascin and microvessel stromal changes in patients with non-Hodgkin's lymphoma are isolated to the sites of disease and vary in correlation to disease activity. Leukemia & Lymphoma. 46: 1455-62. PMID 16194891 DOI: 10.1080/10428190500158060  0.56
2005 Quinn JA, Desjardins A, Weingart J, Brem H, Dolan ME, Delaney SM, Vredenburgh J, Rich J, Friedman AH, Reardon DA, Sampson JH, Pegg AE, Moschel RC, Birch R, McLendon RE, ... ... Bigner DD, et al. Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 7178-87. PMID 16192602 DOI: 10.1200/JCO.2005.06.502  0.56
2005 Cheng CL, Johnson SP, Keir ST, Quinn JA, Ali-Osman F, Szabo C, Li H, Salzman AL, Dolan ME, Modrich P, Bigner DD, Friedman HS. Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft. Molecular Cancer Therapeutics. 4: 1364-8. PMID 16170028 DOI: 10.1158/1535-7163.MCT-05-0128  0.56
2005 McLendon RE, Herndon JE, West B, Reardon D, Wiltshire R, Rasheed BK, Quinn J, Friedman HS, Friedman AH, Bigner DD. Survival analysis of presumptive prognostic markers among oligodendrogliomas. Cancer. 104: 1693-9. PMID 16116609 DOI: 10.1002/cncr.21362  0.56
2005 Graner MW, Bigner DD. Chaperone proteins and brain tumors: potential targets and possible therapeutics. Neuro-Oncology. 7: 260-78. PMID 16053701 DOI: 10.1215/S1152851704001188  0.32
2005 Desjardins A, Rich JN, Quinn JA, Vredenburgh J, Gururangan S, Sathornsumetee S, Reardon DA, Friedman AH, Bigner DD, Friedman HS. Chemotherapy and novel therapeutic approaches in malignant glioma. Frontiers in Bioscience : a Journal and Virtual Library. 10: 2645-68. PMID 15970525  0.56
2005 Akabani G, Reardon DA, Coleman RE, Wong TZ, Metzler SD, Bowsher JE, Barboriak DP, Provenzale JM, Greer KL, DeLong D, Friedman HS, Friedman AH, Zhao XG, Pegram CN, McLendon RE, ... Bigner DD, et al. Dosimetry and radiographic analysis of 131I-labeled anti-tenascin 81C6 murine monoclonal antibody in newly diagnosed patients with malignant gliomas: a phase II study. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 46: 1042-51. PMID 15937318  0.56
2005 Rich JN, Hans C, Jones B, Iversen ES, McLendon RE, Rasheed BK, Dobra A, Dressman HK, Bigner DD, Nevins JR, West M. Gene expression profiling and genetic markers in glioblastoma survival. Cancer Research. 65: 4051-8. PMID 15899794 DOI: 10.1158/0008-5472.CAN-04-3936  0.56
2005 Di C, Liao S, Adamson DC, Parrett TJ, Broderick DK, Shi Q, Lengauer C, Cummins JM, Velculescu VE, Fults DW, McLendon RE, Bigner DD, Yan H. Identification of OTX2 as a medulloblastoma oncogene whose product can be targeted by all-trans retinoic acid. Cancer Research. 65: 919-24. PMID 15705891  0.56
2005 Sampson JH, Reardon DA, Friedman AH, Friedman HS, Coleman RE, McLendon RE, Pastan I, Bigner DD. Sustained radiographic and clinical response in patient with bifrontal recurrent glioblastoma multiforme with intracerebral infusion of the recombinant targeted toxin TP-38: case study. Neuro-Oncology. 7: 90-6. PMID 15701286 DOI: 10.1215/S1152851703000589  0.56
2005 Goudar RK, Shi Q, Hjelmeland MD, Keir ST, McLendon RE, Wikstrand CJ, Reese ED, Conrad CA, Traxler P, Lane HA, Reardon DA, Cavenee WK, Wang XF, Bigner DD, Friedman HS, et al. Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. Molecular Cancer Therapeutics. 4: 101-12. PMID 15657358  0.56
2004 Shi Q, Bao S, Maxwell JA, Reese ED, Friedman HS, Bigner DD, Wang XF, Rich JN. Secreted protein acidic, rich in cysteine (SPARC), mediates cellular survival of gliomas through AKT activation. The Journal of Biological Chemistry. 279: 52200-9. PMID 15469933 DOI: 10.1074/jbc.M409630200  0.56
2004 Shankar S, Vaidyanathan G, Affleck DJ, Peixoto K, Bigner DD, Zalutsky MR. Evaluation of an internalizing monoclonal antibody labeled using N-succinimidyl 3-[131I]iodo-4-phosphonomethylbenzoate ([131I]SIPMB), a negatively charged substituent bearing acylation agent. Nuclear Medicine and Biology. 31: 909-19. PMID 15464393 DOI: 10.1016/j.nucmedbio.2004.04.007  0.48
2004 Bacolod MD, Johnson SP, Pegg AE, Dolan ME, Moschel RC, Bullock NS, Fang Q, Colvin OM, Modrich P, Bigner DD, Friedman HS. Brain tumor cell lines resistant to O6-benzylguanine/1,3-bis(2-chloroethyl)-1-nitrosourea chemotherapy have O6-alkylguanine-DNA alkyltransferase mutations. Molecular Cancer Therapeutics. 3: 1127-35. PMID 15367707  0.56
2004 Boskovitz A, Wikstrand CJ, Kuan CT, Zalutsky MR, Reardon DA, Bigner DD. Monoclonal antibodies for brain tumour treatment. Expert Opinion On Biological Therapy. 4: 1453-71. PMID 15335313 DOI: 10.1517/14712598.4.9.1453  0.52
2004 Broderick DK, Di C, Parrett TJ, Samuels YR, Cummins JM, McLendon RE, Fults DW, Velculescu VE, Bigner DD, Yan H. Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas. Cancer Research. 64: 5048-50. PMID 15289301 DOI: 10.1158/0008-5472.CAN-04-1170  0.56
2004 Merrill MK, Bernhardt G, Sampson JH, Wikstrand CJ, Bigner DD, Gromeier M. Poliovirus receptor CD155-targeted oncolysis of glioma. Neuro-Oncology. 6: 208-17. PMID 15279713 DOI: 10.1215/S1152851703000577  0.56
2004 Wiltshire RN, Herndon JE, Lloyd A, Friedman HS, Bigner DD, Bigner SH, McLendon RE. Comparative genomic hybridization analysis of astrocytomas: prognostic and diagnostic implications. The Journal of Molecular Diagnostics : Jmd. 6: 166-79. PMID 15269292 DOI: 10.1016/S1525-1578(10)60507-7  0.56
2004 Hjelmeland MD, Hjelmeland AB, Sathornsumetee S, Reese ED, Herbstreith MH, Laping NJ, Friedman HS, Bigner DD, Wang XF, Rich JN. SB-431542, a small molecule transforming growth factor-beta-receptor antagonist, inhibits human glioma cell line proliferation and motility. Molecular Cancer Therapeutics. 3: 737-45. PMID 15210860  0.56
2004 Rich JN, Bigner DD. Development of novel targeted therapies in the treatment of malignant glioma. Nature Reviews. Drug Discovery. 3: 430-46. PMID 15136790 DOI: 10.1038/nrd1380  0.36
2004 Quinn JA, Reardon DA, Friedman AH, Rich JN, Sampson JH, Vredenburgh J, Gururangan S, Provenzale JM, Walker A, Schweitzer H, Bigner DD, Tourt-Uhlig S, Herndon JE, Affronti ML, Jackson S, et al. Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma. Neuro-Oncology. 6: 145-53. PMID 15134629 DOI: 10.1215/S1152851703000498  0.56
2004 Reardon DA, Quinn JA, Rich JN, Gururangan S, Vredenburgh J, Sampson JH, Provenzale JM, Walker A, Badruddoja M, Tourt-Uhlig S, Herndon JE, Dowell JM, Affronti ML, Jackson S, Allen D, ... ... Bigner DD, et al. Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma. Neuro-Oncology. 6: 134-44. PMID 15134628 DOI: 10.1215/S1152851703000413  0.56
2004 Learn CA, Hartzell TL, Wikstrand CJ, Archer GE, Rich JN, Friedman AH, Friedman HS, Bigner DD, Sampson JH. Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 3216-24. PMID 15131063 DOI: 10.1158/1078-0432.CCR-03-0521  0.56
2004 Rizzieri DA, Akabani G, Zalutsky MR, Coleman RE, Metzler SD, Bowsher JE, Toaso B, Anderson E, Lagoo A, Clayton S, Pegram CN, Moore JO, Gockerman JP, DeCastro C, Gasparetto C, ... ... Bigner DD, et al. Phase 1 trial study of 131I-labeled chimeric 81C6 monoclonal antibody for the treatment of patients with non-Hodgkin lymphoma. Blood. 104: 642-8. PMID 15100153 DOI: 10.1182/blood-2003-12-4264  0.48
2004 Boskovitz A, Akabani GH, Pegram CN, Bigner DD, Zalutsky MR. Human/murine chimeric 81C6 F(ab')(2) fragment: preclinical evaluation of a potential construct for the targeted radiotherapy of malignant glioma. Nuclear Medicine and Biology. 31: 345-55. PMID 15028247 DOI: 10.1016/j.nucmedbio.2003.10.008  0.48
2004 Castillo MS, Davis FG, Surawicz T, Bruner JM, Bigner S, Coons S, Bigner DD. Consistency of primary brain tumor diagnoses and codes in cancer surveillance systems. Neuroepidemiology. 23: 85-93. PMID 14739573 DOI: 10.1159/000073980  0.56
2004 Rich JN, Reardon DA, Peery T, Dowell JM, Quinn JA, Penne KL, Wikstrand CJ, Van Duyn LB, Dancey JE, McLendon RE, Kao JC, Stenzel TT, Ahmed Rasheed BK, Tourt-Uhlig SE, Herndon JE, ... ... Bigner DD, et al. Phase II trial of gefitinib in recurrent glioblastoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 133-42. PMID 14638850 DOI: 10.1200/JCO.2004.08.110  0.56
2003 Grossi PM, Ochiai H, Archer GE, McLendon RE, Zalutsky MR, Friedman AH, Friedman HS, Bigner DD, Sampson JH. Efficacy of intracerebral microinfusion of trastuzumab in an athymic rat model of intracerebral metastatic breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 9: 5514-20. PMID 14654531  0.56
2003 Sampson JH, Akabani G, Archer GE, Bigner DD, Berger MS, Friedman AH, Friedman HS, Herndon JE, Kunwar S, Marcus S, McLendon RE, Paolino A, Penne K, Provenzale J, Quinn J, et al. Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. Journal of Neuro-Oncology. 65: 27-35. PMID 14649883 DOI: 10.1023/A:1026290315809  0.56
2003 Heimberger AB, Crotty LE, Archer GE, Hess KR, Wikstrand CJ, Friedman AH, Friedman HS, Bigner DD, Sampson JH. Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 9: 4247-54. PMID 14519652  0.56
2003 Fecci PE, Mitchell DA, Archer GE, Morse MA, Lyerly HK, Bigner DD, Sampson JH. The history, evolution, and clinical use of dendritic cell-based immunization strategies in the therapy of brain tumors. Journal of Neuro-Oncology. 64: 161-76. PMID 12952297 DOI: 10.1023/A:1024943506506  0.56
2003 Vaidyanathan G, Affleck DJ, Bigner DD, Zalutsky MR. N-succinimidyl 3-[211At]astato-4-guanidinomethylbenzoate: an acylation agent for labeling internalizing antibodies with alpha-particle emitting 211At. Nuclear Medicine and Biology. 30: 351-9. PMID 12767391  0.48
2003 Rich JN, Shi Q, Hjelmeland M, Cummings TJ, Kuan CT, Bigner DD, Counter CM, Wang XF. Bone-related genes expressed in advanced malignancies induce invasion and metastasis in a genetically defined human cancer model. The Journal of Biological Chemistry. 278: 15951-7. PMID 12590137 DOI: 10.1074/jbc.M211498200  0.56
2003 Quinn JA, Reardon DA, Friedman AH, Rich JN, Sampson JH, Provenzale JM, McLendon RE, Gururangan S, Bigner DD, Herndon JE, Avgeropoulos N, Finlay J, Tourt-Uhlig S, Affronti ML, Evans B, et al. Phase II trial of temozolomide in patients with progressive low-grade glioma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 21: 646-51. PMID 12586801 DOI: 10.1200/JCO.2003.01.009  0.56
2002 Friedman HS, Keir S, Pegg AE, Houghton PJ, Colvin OM, Moschel RC, Bigner DD, Dolan ME. O6-benzylguanine-mediated enhancement of chemotherapy. Molecular Cancer Therapeutics. 1: 943-8. PMID 12481416  0.56
2002 Bacolod MD, Johnson SP, Ali-Osman F, Modrich P, Bullock NS, Colvin OM, Bigner DD, Friedman HS. Mechanisms of resistance to 1,3-bis(2-chloroethyl)-1-nitrosourea in human medulloblastoma and rhabdomyosarcoma. Molecular Cancer Therapeutics. 1: 727-36. PMID 12479369  0.56
2002 Heimberger AB, Learn CA, Archer GE, McLendon RE, Chewning TA, Tuck FL, Pracyk JB, Friedman AH, Friedman HS, Bigner DD, Sampson JH. Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (iressa). Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 8: 3496-502. PMID 12429640  0.56
2002 Akabani G, McLendon RE, Bigner DD, Zalutsky MR. Vascular targeted endoradiotherapy of tumors using alpha-particle-emitting compounds: theoretical analysis. International Journal of Radiation Oncology, Biology, Physics. 54: 1259-75. PMID 12419456  0.56
2002 Rasheed A, Herndon JE, Stenzel TT, Raetz JG, Kendelhardt J, Friedman HS, Friedman AH, Bigner DD, Bigner SH, McLendon RE. Molecular markers of prognosis in astrocytic tumors. Cancer. 94: 2688-97. PMID 12173338 DOI: 10.1002/cncr.10544  0.56
2002 Quinn JA, Pluda J, Dolan ME, Delaney S, Kaplan R, Rich JN, Friedman AH, Reardon DA, Sampson JH, Colvin OM, Haglund MM, Pegg AE, Moschel RC, McLendon RE, Provenzale JM, ... ... Bigner DD, et al. Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 20: 2277-83. PMID 11980998 DOI: 10.1200/JCO.2002.09.084  0.56
2002 Aldosari N, Wiltshire RN, Dutra A, Schrock E, McLendon RE, Friedman HS, Bigner DD, Bigner SH. Comprehensive molecular cytogenetic investigation of chromosomal abnormalities in human medulloblastoma cell lines and xenograft. Neuro-Oncology. 4: 75-85. PMID 11916498 DOI: 10.1215/S1522851701000059  0.56
2002 Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, Herndon JE, Cokgor I, McLendon RE, Pegram CN, Provenzale JM, Quinn JA, Rich JN, Regalado LV, Sampson JH, Shafman TD, ... ... Bigner DD, et al. Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 20: 1389-97. PMID 11870184 DOI: 10.1200/JCO.20.5.1389  0.56
2002 Wikstrand CJ, Cole VR, Crotty LE, Sampson JH, Bigner DD. Generation of anti-idiotypic reagents in the EGFRvIII tumor-associated antigen system. Cancer Immunology, Immunotherapy : Cii. 50: 639-52. PMID 11862416 DOI: 10.1007/s00262-001-0243-5  0.56
2002 Heimberger AB, Archer GE, Crotty LE, McLendon RE, Friedman AH, Friedman HS, Bigner DD, Sampson JH. Dendritic cells pulsed with a tumor-specific peptide induce long-lasting immunity and are effective against murine intracerebral melanoma. Neurosurgery. 50: 158-64; discussion 1. PMID 11844246 DOI: 10.1097/00006123-200201000-00024  0.56
2002 Vaidyanathan G, Affleck DJ, Bigner DD, Zalutsky MR. Improved xenograft targeting of tumor-specific anti-epidermal growth factor receptor variant III antibody labeled using N-succinimidyl 4-guanidinomethyl-3-iodobenzoate. Nuclear Medicine and Biology. 29: 1-11. PMID 11786270  0.48
2001 Friedman HS, Keir ST, Houghton PJ, Lawless AA, Bigner DD, Waters SJ. Activity of irofulven (6-hydroxymethylacylfulvene) in the treatment of glioblastoma multiforme-derived xenografts in athymic mice. Cancer Chemotherapy and Pharmacology. 48: 413-6. PMID 11761460 DOI: 10.1007/s002800100358  0.56
2001 Cavazos CM, Keir ST, Yoshinari T, Bigner DD, Friedman HS. Therapeutic activity of the topoisomerase I inhibitor J-107088 [6-N-(1-hydroxymethyla-2-hydroxyl) ethylamino-12,13-dihydro-13-(beta-D-glucopyranosyl) -5H-indolo[2,3-a]-pyrrolo[3,4-c]-carbazole-5,7(6H)-dione]] against pediatric and adult central nervous system tumor xenografts. Cancer Chemotherapy and Pharmacology. 48: 250-4. PMID 11592348  0.56
2001 Foulon CF, Welsh PC, Bigner DD, Zalutsky MR. Positively charged templates for labeling internalizing antibodies: comparison of N-succinimidyl 5-iodo-3-pyridinecarboxylate and the D-amino acid peptide KRYRR. Nuclear Medicine and Biology. 28: 769-77. PMID 11578897  0.48
2001 Keir ST, Hausheer F, Lawless AA, Bigner DD, Friedman HS. Therapeutic activity of 7-[(2-trimethylsilyl)ethyl)]-20 (S)-camptothecin against central nervous system tumor-derived xenografts in athymic mice. Cancer Chemotherapy and Pharmacology. 48: 83-7. PMID 11488529  0.56
2001 Kuan CT, Wikstrand CJ, Bigner DD. EGF mutant receptor vIII as a molecular target in cancer therapy. Endocrine-Related Cancer. 8: 83-96. PMID 11397666  0.52
2001 Cokgor I, Akabani G, Friedman HS, Friedman AH, Zalutsky MR, Zehngebot LM, Provenzale JM, Guy CD, Wikstrand CJ, Bigner DD. Long term response in a patient with neoplastic meningitis secondary to melanoma treated with (131)I-radiolabeled antichondroitin proteoglycan sulfate Mel-14 F(ab')(2): a case study. Cancer. 91: 1809-13. PMID 11335907 DOI: 10.1002/1097-0142(20010501)91:9<1809::AID-CNCR1200>3.0.CO;2-L  0.56
2001 Rich JN, Guo C, McLendon RE, Bigner DD, Wang XF, Counter CM. A genetically tractable model of human glioma formation. Cancer Research. 61: 3556-60. PMID 11325817  0.56
2000 Kuan CT, Wikstrand CJ, Bigner DD. EGFRvIII as a promising target for antibody-based brain tumor therapy. Brain Tumor Pathology. 17: 71-8. PMID 11210174  0.52
2000 Kuan CT, Wikstrand CJ, Archer G, Beers R, Pastan I, Zalutsky MR, Bigner DD. Increased binding affinity enhances targeting of glioma xenografts by EGFRvIII-specific scFv. International Journal of Cancer. Journal International Du Cancer. 88: 962-9. PMID 11093822 DOI: 10.1002/1097-0215(20001215)88:6<962::AID-IJC20>3.0.CO;2-U  0.52
2000 Cokgor I, Akabani G, Kuan CT, Friedman HS, Friedman AH, Coleman RE, McLendon RE, Bigner SH, Zhao XG, Garcia-Turner AM, Pegram CN, Wikstrand CJ, Shafman TD, Herndon JE, Provenzale JM, ... ... Bigner DD, et al. Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 18: 3862-72. PMID 11078500  0.56
2000 Patel VJ, Elion GB, Houghton PJ, Keir S, Pegg AE, Johnson SP, Dolan ME, Bigner DD, Friedman HS. Schedule-dependent activity of temozolomide plus CPT-11 against a human central nervous system tumor-derived xenograft. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 6: 4154-7. PMID 11051270  0.56
2000 Heimberger AB, Archer GE, McLendon RE, Hulette C, Friedman AH, Friedman HS, Bigner DD, Sampson JH. Temozolomide delivered by intracerebral microinfusion is safe and efficacious against malignant gliomas in rats. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 6: 4148-53. PMID 11051269  0.56
2000 Friedman HS, Pluda J, Quinn JA, Ewesuedo RB, Long L, Friedman AH, Cokgor I, Colvin OM, Haglund MM, Ashley DM, Rich JN, Sampson J, Pegg AE, Moschel RC, McLendon RE, ... ... Bigner DD, et al. Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 18: 3522-8. PMID 11032594  0.56
2000 Loging WT, Lal A, Siu IM, Loney TL, Wikstrand CJ, Marra MA, Prange C, Bigner DD, Strausberg RL, Riggins GJ. Identifying potential tumor markers and antigens by database mining and rapid expression screening. Genome Research. 10: 1393-402. PMID 10984457 DOI: 10.1101/gr.138000  0.56
2000 Foulon CF, Reist CJ, Bigner DD, Zalutsky MR. Radioiodination via D-amino acid peptide enhances cellular retention and tumor xenograft targeting of an internalizing anti-epidermal growth factor receptor variant III monoclonal antibody. Cancer Research. 60: 4453-60. PMID 10969792  0.48
2000 Campa MJ, Kuan CT, O'Connor-McCourt MD, Bigner DD, Patz EF. Design of a novel small peptide targeted against a tumor-specific receptor. Biochemical and Biophysical Research Communications. 275: 631-6. PMID 10964715 DOI: 10.1006/bbrc.2000.3347  0.56
2000 McLendon RE, Wikstrand CJ, Matthews MR, Al-Baradei R, Bigner SH, Bigner DD. Glioma-associated antigen expression in oligodendroglial neoplasms. Tenascin and epidermal growth factor receptor. The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society. 48: 1103-10. PMID 10898803  0.56
2000 Keir ST, Dolan ME, Pegg AE, Lawless A, Moschel RC, Bigner DD, Friedman HS. O6-benzylguanine-mediated enhancement of nitrosourea activity in Mer- central nervous system tumor xenografts--implications for clinical trials. Cancer Chemotherapy and Pharmacology. 45: 437-40. PMID 10854129  0.56
2000 Sampson JH, Crotty LE, Lee S, Archer GE, Ashley DM, Wikstrand CJ, Hale LP, Small C, Dranoff G, Friedman AH, Friedman HS, Bigner DD. Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors. Proceedings of the National Academy of Sciences of the United States of America. 97: 7503-8. PMID 10852962 DOI: 10.1073/pnas.130166597  0.56
2000 Aldosari N, Rasheed BK, McLendon RE, Friedman HS, Bigner DD, Bigner SH. Characterization of chromosome 17 abnormalities in medulloblastomas. Acta Neuropathologica. 99: 345-51. PMID 10787031  0.56
2000 Castellino RC, Elion GB, Keir ST, Houghton PJ, Johnson SP, Bigner DD, Friedman HS. Schedule-dependent activity of irinotecan plus BCNU against malignant glioma xenografts. Cancer Chemotherapy and Pharmacology. 45: 345-9. PMID 10755324 DOI: 10.1007/s002800050050  0.56
2000 Akabani G, Cokgor I, Coleman RE, González Trotter D, Wong TZ, Friedman HS, Friedman AH, Garcia-Turner A, Herndon JE, DeLong D, McLendon RE, Zhao XG, Pegram CN, Provenzale JM, Bigner DD, et al. Dosimetry and dose-response relationships in newly diagnosed patients with malignant gliomas treated with iodine-131-labeled anti-tenascin monoclonal antibody 81C6 therapy. International Journal of Radiation Oncology, Biology, Physics. 46: 947-58. PMID 10705017  0.56
2000 Heimberger AB, Crotty LE, Archer GE, McLendon RE, Friedman A, Dranoff G, Bigner DD, Sampson JH. Bone marrow-derived dendritic cells pulsed with tumor homogenate induce immunity against syngeneic intracerebral glioma. Journal of Neuroimmunology. 103: 16-25. PMID 10674985 DOI: 10.1016/S0165-5728(99)00172-1  0.56
1999 Wikstrand CJ, Cokgor I, Sampson JH, Bigner DD. Monoclonal antibody therapy of human gliomas: current status and future approaches. Cancer Metastasis Reviews. 18: 451-64. PMID 10855788  0.56
1999 Archer GE, Sampson JH, McLendon RE, Friedman AH, Colvin OM, Rose M, Sands H, McCullough W, Fuchs HE, Bigner DD, Friedman HS. Intrathecal busulfan treatment of human neoplastic meningitis in athymic nude rats. Journal of Neuro-Oncology. 44: 233-41. PMID 10720203 DOI: 10.1023/A:1006304424346  0.56
1999 Rich JN, Zhang M, Datto MB, Bigner DD, Wang XF. Transforming growth factor-beta-mediated p15(INK4B) induction and growth inhibition in astrocytes is SMAD3-dependent and a pathway prominently altered in human glioma cell lines. The Journal of Biological Chemistry. 274: 35053-8. PMID 10574984  0.36
1999 Foulon CF, Bigner DD, Zalutsky MR. Preparation and characterization of anti-tenascin monoclonal antibody-streptavidin conjugates for pretargeting applications. Bioconjugate Chemistry. 10: 867-76. PMID 10502355  0.48
1999 Archer GE, Sampson JH, Lorimer IA, McLendon RE, Kuan CT, Friedman AH, Friedman HS, Pastan IH, Bigner DD. Regional treatment of epidermal growth factor receptor vIII-expressing neoplastic meningitis with a single-chain immunotoxin, MR-1. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 5: 2646-52. PMID 10499644  0.56
1999 McLendon RE, Archer GE, Larsen RH, Akabani G, Bigner DD, Zalutsky MR. Radiotoxicity of systemically administered 211At-labeled human/mouse chimeric monoclonal antibody: a long-term survival study with histologic analysis. International Journal of Radiation Oncology, Biology, Physics. 45: 491-9. PMID 10487576 DOI: 10.1016/S0360-3016(99)00206-0  0.56
1999 Bigner SH, Matthews MR, Rasheed BK, Wiltshire RN, Friedman HS, Friedman AH, Stenzel TT, Dawes DM, McLendon RE, Bigner DD. Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization. The American Journal of Pathology. 155: 375-86. PMID 10433931 DOI: 10.1016/S0002-9440(10)65134-6  0.56
1999 Kuan CT, Reist CJ, Foulon CF, Lorimer IA, Archer G, Pegram CN, Pastan I, Zalutsky MR, Bigner DD. 125I-labeled anti-epidermal growth factor receptor-vIII single-chain Fv exhibits specific and high-level targeting of glioma xenografts. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 5: 1539-49. PMID 10389943  0.56
1999 Reist CJ, Foulon CF, Alston K, Bigner DD, Zalutsky MR. Astatine-211 labeling of internalizing anti-EGFRvIII monoclonal antibody using N-succinimidyl 5-[211At]astato-3-pyridinecarboxylate. Nuclear Medicine and Biology. 26: 405-11. PMID 10382844 DOI: 10.1016/S0969-8051(98)00120-6  0.56
1999 Sampson JH, Archer GE, Villavicencio AT, McLendon RE, Friedman AH, Bishop WR, Bigner DD, Friedman HS. Treatment of neoplastic meningitis with intrathecal temozolomide. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 5: 1183-8. PMID 10353755  0.56
1999 Friedman HS, Petros WP, Friedman AH, Schaaf LJ, Kerby T, Lawyer J, Parry M, Houghton PJ, Lovell S, Rasheed K, Cloughsey T, Stewart ES, Colvin OM, Provenzale JM, McLendon RE, ... Bigner DD, et al. Irinotecan therapy in adults with recurrent or progressive malignant glioma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 17: 1516-25. PMID 10334539  0.56
1999 Rasheed BK, Wiltshire RN, Bigner SH, Bigner DD. Molecular pathogenesis of malignant gliomas. Current Opinion in Oncology. 11: 162-7. PMID 10328589 DOI: 10.1097/00001622-199905000-00004  0.56
1999 Akabani G, Reist CJ, Cokgor I, Friedman AH, Friedman HS, Coleman RE, Zhao XG, Bigner DD, Zalutsky MR. Dosimetry of 131I-labeled 81C6 monoclonal antibody administered into surgically created resection cavities in patients with malignant brain tumors. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 40: 631-8. PMID 10210222  0.56
1999 Friedman HS, Pegg AE, Johnson SP, Loktionova NA, Dolan ME, Modrich P, Moschel RC, Struck R, Brent TP, Ludeman S, Bullock N, Kilborn C, Keir S, Dong Q, Bigner DD, et al. Modulation of cyclophosphamide activity by O6-alkylguanine-DNA alkyltransferase. Cancer Chemotherapy and Pharmacology. 43: 80-5. PMID 9923545 DOI: 10.1007/s002800050866  0.56
1999 Dong Q, Johnson SP, Colvin OM, Bullock N, Kilborn C, Runyon G, Sullivan DM, Easton J, Bigner DD, Nahta R, Marks J, Modrich P, Friedman HS. Multiple DNA repair mechanisms and alkylator resistance in the human medulloblastoma cell line D-283 Med (4-HCR). Cancer Chemotherapy and Pharmacology. 43: 73-9. PMID 9923544 DOI: 10.1007/s002800050865  0.56
1998 Friedman HS, McLendon RE, Kerby T, Dugan M, Bigner SH, Henry AJ, Ashley DM, Krischer J, Lovell S, Rasheed K, Marchev F, Seman AJ, Cokgor I, Rich J, Stewart E, ... ... Bigner DD, et al. DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 16: 3851-7. PMID 9850030  0.56
1998 Friedman HS, Kokkinakis DM, Pluda J, Friedman AH, Cokgor I, Haglund MM, Ashley DM, Rich J, Dolan ME, Pegg AE, Moschel RC, McLendon RE, Kerby T, Herndon JE, Bigner DD, et al. Phase I trial of O6-benzylguanine for patients undergoing surgery for malignant glioma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 16: 3570-5. PMID 9817277  0.56
1998 Reist CJ, Bigner DD, Zalutsky MR. Human IgG2 constant region enhances in vivo stability of anti-tenascin antibody 81C6 compared with its murine parent. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 4: 2495-502. PMID 9796983  0.48
1998 Hanley ML, Elion GB, Colvin OM, Modrich PL, Keir S, Adams DJ, Bigner DD, Friedman HS. Therapeutic efficacy of vinorelbine against pediatric and adult central nervous system tumors. Cancer Chemotherapy and Pharmacology. 42: 479-82. PMID 9788574 DOI: 10.1007/s002800050848  0.56
1998 Ashley DM, Sampson JH, Archer GE, Hale LP, Bigner DD. Local production of TGF beta1 inhibits cerebral edema, enhances TNF-alpha induced apoptosis and improves survival in a murine glioma model. Journal of Neuroimmunology. 86: 46-52. PMID 9655471 DOI: 10.1016/S0165-5728(98)00017-4  0.56
1998 Lee SE, Johnson SP, Hale LP, Li J, Bullock N, Fuchs H, Friedman A, McLendon R, Bigner DD, Modrich P, Friedman HS. Analysis of DNA mismatch repair proteins in human medulloblastoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 4: 1415-9. PMID 9626457  0.56
1998 Bigner DD, Brown MT, Friedman AH, Coleman RE, Akabani G, Friedman HS, Thorstad WL, McLendon RE, Bigner SH, Zhao XG, Pegram CN, Wikstrand CJ, Herndon JE, Vick NA, Paleologos N, et al. Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 16: 2202-12. PMID 9626222  0.56
1998 Wikstrand CJ, Bigner DD. Prognostic applications of the epidermal growth factor receptor and its ligand, transforming growth factor-alpha. Journal of the National Cancer Institute. 90: 799-801. PMID 9625163  0.32
1998 McLendon RE, Cleveland L, Pegram C, Bigner SH, Bigner DD, Friedman HS. Immunohistochemical detection of the DNA repair enzyme O6-methylguanine-DNA methyltransferase in formalin-fixed, paraffin-embedded astrocytomas. Laboratory Investigation; a Journal of Technical Methods and Pathology. 78: 643-4. PMID 9605190  0.56
1998 Wikstrand CJ, Reist CJ, Archer GE, Zalutsky MR, Bigner DD. The class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immunotherapeutic target. Journal of Neurovirology. 4: 148-58. PMID 9584952 DOI: 10.3109/13550289809114515  0.56
1998 Coggins CA, Elion GB, Houghton PJ, Hare CB, Keir S, Colvin OM, Bigner DD, Friedman HS. Enhancement of irinotecan (CPT-11) activity against central nervous system tumor xenografts by alkylating agents. Cancer Chemotherapy and Pharmacology. 41: 485-90. PMID 9554593 DOI: 10.1007/s002800050771  0.56
1998 Ashley DM, Kong FM, Bigner DD, Hale LP. Endogenous expression of transforming growth factor beta1 inhibits growth and tumorigenicity and enhances Fas-mediated apoptosis in a murine high-grade glioma model. Cancer Research. 58: 302-9. PMID 9443409  0.32
1997 Hauck ML, Dewhirst MW, Bigner DD, Zalutsky MR. Local hyperthermia improves uptake of a chimeric monoclonal antibody in a subcutaneous xenograft model. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 3: 63-70. PMID 9815539  0.48
1997 Ashley DM, Batra SK, Bigner DD. Monoclonal antibodies to growth factors and growth factor receptors: their diagnostic and therapeutic potential in brain tumors. Journal of Neuro-Oncology. 35: 259-73. PMID 9440024 DOI: 10.1023/A:1005812417638  0.56
1997 Ashley DM, Bigner DD. Recent advances in the biology of central nervous system tumors. Current Opinion in Neurology. 10: 445-51. PMID 9425557  0.32
1997 Sampson JH, Ashley DM, Archer GE, Fuchs HE, Dranoff G, Hale LP, Bigner DD. Characterization of a spontaneous murine astrocytoma and abrogation of its tumorigenicity by cytokine secretion. Neurosurgery. 41: 1365-72; discussion . PMID 9402588  0.56
1997 Reist CJ, Batra SK, Pegram CN, Bigner DD, Zalutsky MR. In vitro and in vivo behavior of radiolabeled chimeric anti-EGFRvIII monoclonal antibody: comparison with its murine parent. Nuclear Medicine and Biology. 24: 639-47. PMID 9352535  0.48
1997 Rasheed BK, Stenzel TT, McLendon RE, Parsons R, Friedman AH, Friedman HS, Bigner DD, Bigner SH. PTEN gene mutations are seen in high-grade but not in low-grade gliomas. Cancer Research. 57: 4187-90. PMID 9331072  0.56
1997 Ashley DM, Faiola B, Nair S, Hale LP, Bigner DD, Gilboa E. Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. The Journal of Experimental Medicine. 186: 1177-82. PMID 9314567 DOI: 10.1084/jem.186.7.1177  0.56
1997 Wikstrand CJ, McLendon RE, Friedman AH, Bigner DD. Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII. Cancer Research. 57: 4130-40. PMID 9307304  0.56
1997 Ashley DM, Sampson JH, Archer GE, Batra SK, Bigner DD, Hale LP. A genetically modified allogeneic cellular vaccine generates MHC class I-restricted cytotoxic responses against tumor-associated antigens and protects against CNS tumors in vivo. Journal of Neuroimmunology. 78: 34-46. PMID 9307226 DOI: 10.1016/S0165-5728(97)00080-5  0.56
1997 Hare CB, Elion GB, Colvin OM, Ali-Osman F, Griffith OW, Petros WP, Keir S, Marcelli SL, Bigner DD, Friedman HS. Characterization of the mechanisms of busulfan resistance in a human glioblastoma multiforme xenograft. Cancer Chemotherapy and Pharmacology. 40: 409-14. PMID 9272117 DOI: 10.1007/s002800050678  0.56
1997 Friedman HS, Johnson SP, Dong Q, Schold SC, Rasheed BK, Bigner SH, Ali-Osman F, Dolan E, Colvin OM, Houghton P, Germain G, Drummond JT, Keir S, Marcelli S, Bigner DD, et al. Methylator resistance mediated by mismatch repair deficiency in a glioblastoma multiforme xenograft. Cancer Research. 57: 2933-6. PMID 9230204  0.56
1997 Zalutsky MR, Stabin MG, Larsen RH, Bigner DD. Tissue distribution and radiation dosimetry of astatine-211-labeled chimeric 81C6, an alpha-particle-emitting immunoconjugate. Nuclear Medicine and Biology. 24: 255-61. PMID 9228660  0.48
1997 Chu CT, Everiss KD, Wikstrand CJ, Batra SK, Kung HJ, Bigner DD. Receptor dimerization is not a factor in the signalling activity of a transforming variant epidermal growth factor receptor (EGFRvIII). The Biochemical Journal. 324: 855-61. PMID 9210410  0.32
1997 Archer GE, Sampson JH, Bigner DD. Viruses and oncogenes in brain tumors. Journal of Neurovirology. 3: S76-7. PMID 9179801  0.56
1997 Reist CJ, Archer GE, Wikstrand CJ, Bigner DD, Zalutsky MR. Improved targeting of an anti-epidermal growth factor receptor variant III monoclonal antibody in tumor xenografts after labeling using N-succinimidyl 5-iodo-3-pyridinecarboxylate. Cancer Research. 57: 1510-5. PMID 9108453  0.56
1997 Kurpad SN, Dolan ME, McLendon RE, Archer GE, Moschel RC, Pegg AE, Bigner DD, Friedman HS. Intraarterial O6-benzylguanine enables the specific therapy of nitrosourea-resistant intracranial human glioma xenografts in athymic rats with 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Chemotherapy and Pharmacology. 39: 307-16. PMID 9025771 DOI: 10.1007/s002800050577  0.56
1997 Hare CB, Elion GB, Houghton PJ, Houghton JA, Keir S, Marcelli SL, Bigner DD, Friedman HS. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against pediatric and adult central nervous system tumor xenografts. Cancer Chemotherapy and Pharmacology. 39: 187-91. PMID 8996518 DOI: 10.1007/s002800050558  0.56
1997 Moynihan K, Elion GB, Pegram C, Reist CJ, Wellner D, Bigner DD, Griffith OW, Friedman HS. L-amino acid oxidase (LOX) modulation of melphalan activity against intracranial glioma. Cancer Chemotherapy and Pharmacology. 39: 179-86. PMID 8996517 DOI: 10.1007/s002800050557  0.56
1996 Brown MT, Coleman RE, Friedman AH, Friedman HS, McLendon RE, Reiman R, Felsberg GJ, Tien RD, Bigner SH, Zalutsky MR, Zhao XG, Wikstrand CJ, Pegram CN, Herndon JE, Vick NA, ... ... Bigner DD, et al. Intrathecal 131I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: phase I trial results. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 2: 963-72. PMID 9816257  0.56
1996 Lorimer IA, Keppler-Hafkemeyer A, Beers RA, Pegram CN, Bigner DD, Pastan I. Recombinant immunotoxins specific for a mutant epidermal growth factor receptor: targeting with a single chain antibody variable domain isolated by phage display. Proceedings of the National Academy of Sciences of the United States of America. 93: 14815-20. PMID 8962138 DOI: 10.1073/pnas.93.25.14815  0.56
1996 Reist CJ, Garg PK, Alston KL, Bigner DD, Zalutsky MR. Radioiodination of internalizing monoclonal antibodies using N-succinimidyl 5-iodo-3-pyridinecarboxylate. Cancer Research. 56: 4970-7. PMID 8895752  0.56
1996 Zalutsky MR, Archer GE, Garg PK, Batra SK, Bigner DD. Chimeric anti-tenascin antibody 81C6: increased tumor localization compared with its murine parent. Nuclear Medicine and Biology. 23: 449-58. PMID 8832699 DOI: 10.1016/0969-8051(96)00021-2  0.56
1996 Sampson JH, Archer GE, Ashley DM, Fuchs HE, Hale LP, Dranoff G, Bigner DD. Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system. Proceedings of the National Academy of Sciences of the United States of America. 93: 10399-404. PMID 8816812  0.56
1996 Fredman P, Wikstrand CJ, MÃ¥nsson JE, Reifenberger G, Bigner SH, Rasheed A, Svennerholm L, Bigner DD. In vivo growth conditions suppress the expression of ganglioside GM2 and favour that of lacto series gangliosides in the human glioma D-54MG cell line. Glycoconjugate Journal. 13: 391-9. PMID 8781970 DOI: 10.1007/BF00731472  0.56
1996 Zalutsky MR, Schuster JM, Garg PK, Archer GE, Dewhirst MW, Bigner DD. Two approaches for enhancing radioimmunotherapy: alpha emitters and hyperthermia. Recent Results in Cancer Research. Fortschritte Der Krebsforschung. ProgrèS Dans Les Recherches Sur Le Cancer. 141: 101-22. PMID 8722422  0.56
1996 Davis FG, Malinski N, Haenszel W, Chang J, Flannery J, Gershman S, Dibble R, Bigner DD. Primary brain tumor incidence rates in four United States regions, 1985-1989: a pilot study. Neuroepidemiology. 15: 103-12. PMID 8684582  0.56
1996 Zalutsky MR, Bigner DD. Radioimmunotherapy with alpha-particle emitting radioimmunoconjugates. Acta Oncologica (Stockholm, Sweden). 35: 373-9. PMID 8679269  0.48
1996 Moynihan K, Elion GB, Ali-Osman F, Marcelli S, Keir S, Bigner DD, Friedman HS. Enhancement of melphalan activity by inhibition of DNA polymerase-alpha and DNA polymerase-beta. Cancer Chemotherapy and Pharmacology. 38: 349-54. PMID 8674158 DOI: 10.1007/s002800050494  0.56
1996 McLendon RE, Archer GE, Garg PK, Bigner DD, Zalutsky MR. Radiotoxicity of systematically administered [211At]astatide in B6C3F1 and BALB/c (nu/nu) mice: a long-term survival study with histologic analysis. International Journal of Radiation Oncology, Biology, Physics. 35: 69-80. PMID 8641929  0.56
1996 McLendon RE, Fung KM, Bentley RC, Ahmed Rasheed BK, Trojanowski JQ, Bigner SH, Bigner DD, Friedman HS. Production and characterization of two ependymoma xenografts. Journal of Neuropathology and Experimental Neurology. 55: 540-8. PMID 8627345  0.56
1996 McCowage G, Tien R, McLendon R, Felsberg G, Fuchs H, Graham ML, Kurtzberg J, Moghrabi A, Ferrell L, Kerby T, Duncan-Brown M, Stewart E, Robertson PL, Colvin OM, Golembe B, ... Bigner DD, et al. Successful treatment of childhood pilocytic astrocytomas metastatic to the leptomeninges with high-dose cyclophosphamide. Medical and Pediatric Oncology. 27: 32-9. PMID 8614389 DOI: 10.1002/(SICI)1096-911X(199607)27:1<32::AID-MPO7>3.0.CO;2-V  0.56
1996 Ashley DM, Longee D, Tien R, Fuchs H, Graham ML, Kurtzberg J, Casey J, Olson J, Meier L, Ferrell L, Kerby T, Duncan-Brown M, Stewart E, Colvin OM, Pipas JM, ... ... Bigner DD, et al. Treatment of patients with pineoblastoma with high dose cyclophosphamide. Medical and Pediatric Oncology. 26: 387-92. PMID 8614374 DOI: 10.1002/(SICI)1096-911X(199606)26:6<387::AID-MPO3>3.0.CO;2-D  0.56
1996 Dong Q, Bullock N, Ali-Osman F, Colvin OM, Bigner DD, Friedman HS. Repair analysis of 4-hydroperoxycyclophosphamide-induced DNA interstrand crosslinking in the c-myc gene in 4-hydroperoxycyclophosphamide-sensitive and -resistant medulloblastoma cell lines. Cancer Chemotherapy and Pharmacology. 37: 242-46. PMID 8529284  0.56
1995 Lorimer IA, Wikstrand CJ, Batra SK, Bigner DD, Pastan I. Immunotoxins that target an oncogenic mutant epidermal growth factor receptor expressed in human tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 1: 859-64. PMID 9816055  0.48
1995 Bigner DD, Archer GE, McLendon RE, Friedman HS, Fuchs HE, Pai LH, Herndon JE, Pastan IH. Efficacy of compartmental administration of immunotoxin LMB-1 (B3-LysPE38) in a rat model of carcinomatous meningitis. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 1: 1545-55. PMID 9815955  0.56
1995 Batra SK, Castelino-Prabhu S, Wikstrand CJ, Zhu X, Humphrey PA, Friedman HS, Bigner DD. Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene. Cell Growth & Differentiation : the Molecular Biology Journal of the American Association For Cancer Research. 6: 1251-9. PMID 8845302  0.56
1995 Dong Q, Barsky D, Colvin ME, Melius CF, Ludeman SM, Moravek JF, Colvin OM, Bigner DD, Modrich P, Friedman HS. A structural basis for a phosphoramide mustard-induced DNA interstrand cross-link at 5'-d(GAC). Proceedings of the National Academy of Sciences of the United States of America. 92: 12170-4. PMID 8618865  0.56
1995 Kurpad SN, Zhao XG, Wikstrand CJ, Batra SK, McLendon RE, Bigner DD. Tumor antigens in astrocytic gliomas. Glia. 15: 244-56. PMID 8586461 DOI: 10.1002/glia.440150306  0.56
1995 Reist CJ, Archer GE, Kurpad SN, Wikstrand CJ, Vaidyanathan G, Willingham MC, Moscatello DK, Wong AJ, Bigner DD, Zalutsky MR. Tumor-specific anti-epidermal growth factor receptor variant III monoclonal antibodies: use of the tyramine-cellobiose radioiodination method enhances cellular retention and uptake in tumor xenografts. Cancer Research. 55: 4375-82. PMID 7671250  0.56
1995 Kurpad SN, Friedman HS, Archer GE, McLendon RE, Petros WM, Fuchs HE, Guaspari A, Bigner DD. Intraarterial administration of melphalan for treatment of intracranial human glioma xenografts in athymic rats. Cancer Research. 55: 3803-9. PMID 7641197  0.56
1975 Copeland DD, Vogel FS, Bigner DD. The induction of intractranial neoplasms by the inoculation of avian sarcoma virus in perinatal and adult rats. Journal of Neuropathology and Experimental Neurology. 34: 340-58. PMID 166146  0.56
Show low-probability matches.